UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended ~~June~~September 30, 2022

Commission File Number 001-35817

VYANT BIO, INC.

(Exact name of registrant as specified in the charter)

Delaware		04-3462475
(State or other jurisdiction of		(I.R.S. Employer
of incorporation or organization)		Identification Number)

2 Executive Campus

2370 State Route 70, Suite 310

Cherry Hill, NJ 08002

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (201) 479-8126

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 Par Value		VYNT		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐.

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐

Non-accelerated Filer ☒ Smaller reporting company ☒

Emerging growth company ☐

If an emerging growth company, indicate by check mark if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒.

There were ~~29,343,183~~5,910,308 shares of common stock, par value $0.0001 of Vyant Bio, Inc. issued and outstanding as of ~~August 18,~~November 10, 2022.

Vyant Bio, Inc. and Subsidiaries

INDEX

		Page No.

Part I	Financial Information	3
Item 1:	Unaudited Condensed Consolidated Financial Statements	3
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2223
Item 3:	Quantitative and Qualitative Disclosures about Market Risk	3132
Item 4:	Controls and Procedures	3132

Part II	Other Information	3233
Item 1:	Legal Proceedings	3233
Item 1A:	Risk Factors	3233
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	3233
Item 3:	Defaults Upon Senior Securities	3233
Item 4:	Mine Safety Disclosures	3233
Item 5:	Other Information	3233
Item 6:	Exhibits	3334

Signatures		3435

Part I Financial Information

Item 1 Financial Statements

Vyant Bio, Inc.

Consolidated Balance Sheets

(unaudited)

(Shares and USD in thousands)

	June 30,			December 31,			September 30,			December 31,
	2022			2021			2022			2021

Assets
Current assets:
Cash and cash equivalents	$	11,702		$	20,608		$	9,394		$	20,608
Trade accounts and other receivables		484			434			383			434
Inventory		437			475			66			475
Prepaid expenses and other current assets		1,524			895			1,161			895
Assets of discontinuing operations – current		2,101			802			1,122			802
Total current assets		16,248			23,214			12,126			23,214
Non-current assets:
Fixed assets, net		1,101			1,020			1,223			1,020
Operating lease right-of-use assets, net		1,691			673			1,617			673
Long-term prepaid expenses and other assets		1,154			1,221			1,110			1,221
Assets of discontinuing operations – non-current		6,617			11,508			6,963			11,508
Total non-current assets		10,563			14,422			10,913			14,422
Total assets	$	26,811		$	37,636		$	23,039		$	37,636

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	1,040		$	740		$	897		$	740
Accrued expenses		1,334			764			1,329			764
Deferred revenue		72			74			72			74
Obligations under operating leases, current portion		293			174			303			174
Obligation under finance lease, current portion		161			157
Obligation under finance leases, current portion								247			157
Liabilities of discontinuing operations – current		4,607			3,522			3,845			3,522
Total current liabilities		7,507			5,431			6,693			5,431
Obligations under operating leases, less current portion		1,463			516			1,383			516
Obligations under finance leases, less current portion		217			293			338			293
Long-term debt		57			57			57			57
Liabilities of discontinuing operations – non-current		780			49			728			49
Total liabilities	$	10,024		$	6,346		$	9,199		$	6,346

Commitments and contingencies		-						-			-

Stockholders’ equity:
Preferred stock, authorized 9,764 shares $0.0001 par value, NaN issued		-			-
Common stock, authorized 100,000 shares, $0.0001 par value, 29,413 and 28,993 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively		3			3
Preferred stock, authorized 9,764 shares $0.0001 par value, none issued								-			-
Common stock, authorized 100,000 shares, $0.0001 par value, 5,883 and 5,798 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively								1			1
Additional paid-in capital		110,627			110,174			111,009			110,176
Accumulated deficit		(93,781	)		(78,813	)		(97,244	)		(78,813	)
Accumulated comprehensive loss		(62	)		(74	)
Total stockholders’ equity		16,787			31,290
Total liabilities and stockholders’ equity	$	26,811		$	37,636
Accumulated comprehensive income (loss)								74			(74	)
Total Stockholders’ equity								13,840			31,290
Total liabilities and Stockholders’ equity							$	23,039		$	37,636

See Notes to Unaudited Condensed Consolidated Financial Statements.

Vyant Bio, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(unaudited)

(Shares and USD in thousands, except per share amounts)

	2022			2021			2022			2021			2022			2021			2022			2021
	Three months ended June 30,						Six months ended June, 30						Three months ended September 30,						Nine months ended September 30,
	2022			2021			2022			2021			2022			2021			2022			2021
Revenue:
Service	$	-		$	213		$	94		$	310		$	-		$	97		$	94		$	407
Product		165			116			374			222			152			159			526			381
Total revenue		165			329			468			532			152			256			620			788

Operating costs and expenses:
Cost of goods sold – service		-			103			38			167			-			110			38			277
Cost of goods sold – product		304			345			652			741			257			355			909			1,096
Cost of goods sold
Research and development		1,688			910			3,239			1,730			1,993			1,211			5,232			2,941
Selling, general and administrative		2,509			2,737			5,272			3,951			1,583			1,856			6,855			5,807
Merger related costs		-			165			-			2,310			-			-			-			2,310
Total operating costs and expenses		4,501			4,260			9,201			8,899			3,833			3,532			13,034			12,431
Loss from operations		(4,336	)		(3,931	)		(8,733	)		(8,367	)		(3,681	)		(3,276	)		(12,414	)		(11,643	)

Other income (expense):
Change in fair value of warrant liability		-			-			-			214			-			-			-			214
Change in fair value of share-settlement obligation derivative		-			-			-			(250	)		-			-			-			(250	)
Loss on debt conversions								-			(2,518	)		-			-			-			(2,518	)
Other income (expense), net		-			(28	)		-			(28	)		5			6			5			(22	)
Interest income (expense), net		11			5			2			(363	)		29			(4	)		31			(367	)
Total other income (expense)		11			(23	)		2			(2,945	)		34			2			36			(2,943	)
Loss from continuing operations before income taxes		(4,325	)		(3,954	)		(8,731	)		(11,312	)		(3,647	)		(3,274	)		(12,378	)		(14,586	)
Income tax expense (benefit)		-			-			-			-			-			-			-			-
Loss from continuing operations		(4,325	)		(3,954	)		(8,731	)		(11,312	)		(3,647	)		(3,274	)		(12,378	)		(14,586	)
Discontinuing operations (net of $44 tax benefit in 2022 and $0 in 2021)		(1,480	)		(232	)		(6,237	)		(240	)
Discontinuing operations (net of $40 and $84 tax benefit in the three and nine months ended September 30, 2022, respectively, and $0 in 2021)														184			(1,187	)		(6,053	)		(1,427	)
Net loss		(5,805	)		(4,186	)		(14,968	)		(11,552	)		(3,463	)		(4,461	)		(18,431	)		(16,013	)
Cumulative translation adjustment		8			-			12			-			136			17			148			16
Comprehensive loss	$	(5,797	)	$	(4,186	)	$	(14,956	)	$	(11,552	)	$	(3,327	)	$	(4,444	)	$	(18,283	)	$	(15,997	)

Net loss per share attributed to common stock – basic and diluted:
Net loss per share from continuing operations	$	(0.15	)	$	(0.13	)	$	(0.30	)	$	(0.70	)	$	(0.62	)	$	(0.57	)	$	(2.11	)	$	(3.56	)
Net loss per share from discontinuing operations		(0.05	)		(0.01	)		(0.21	)		(0.02	)
Net income (loss) per share from discontinuing operations														0.03			(0.20	)		(1.04	)		(0.35	)
Net loss per share	$	(0.20	)	$	(0.14	)	$	(0.51	)	$	(0.72	)	$	(0.59	)	$	(0.77	)	$	(3.15	)	$	(3.91	)
Weighted average shares outstanding:
Weighted average common shares outstanding - Basic and Diluted		29,413			28,986			29,214			16,156			5,883			5,797			5,856			4,096

See Notes to Unaudited Condensed Consolidated Financial Statements.

Vyant Bio, Inc.

Consolidated Statements of ~~Temporary Equity and~~ Common Stockholders’ Equity (Deficit)

(unaudited)

(Shares and USD in thousands)

Shares Amount Capital Deficit Loss Equity
Three months ended June 30, 2022 and 2021

Common Stock Additional Paid In Accumulated
Accumulated
Comprehensive Total
Stockholders’
Shares Amount Capital Deficit Loss Equity
Balance as of April 1, 2022 - - - - 29,412 $ 3 $ 110,411 $ (87,976 ) $ �� (70 ) $ 22,368
Stock-based compensation - - 365 - - 365
Issuance of common stock, net of issuance costs
1
- (149 ) - - (149 )
Foreign currency translation adjustment - - - - 8 8
Net loss - - - - - - - (5,805 ) - (5,805 )
Balance as of June 30, 2022 - - - - 29,413 $ 3 $ 110,627 $ (93,781 ) $ (62 ) $ 16,787

					Shares		Amount		Capital		Deficit			Loss			Equity
Three months ended September 30, 2022 and 2021
					Common Stock				Additional Paid In		Accumulated			Accumulated Comprehensive			Total Stockholders’
					Shares		Amount		Capital		Deficit			Income (Loss)			Equity
Balance as of July 1, 2022	-	-	-	-		5,883	$	1	$	110,629	$	(93,781	)	$	(62	)	$	16,787
Stock-based compensation						-		-		380		-			-			380
Foreign currency translation adjustment						-		-		-		-			136			136
Net loss	-	-	-	-		-		-		-		(3,463	)		-			(3,463	)
Balance as of September 30, 2022	-	-	-	-		5,883	$	1	$	111,009	$	(97,244	)	$	74		$	13,840

					Common Stock				Additional Paid In		Accumulated			Accumulated Comprehensive			Total Stockholders’			Shares		Amount		Capital		Deficit			Loss			Equity
					Shares		Amount		Capital		Deficit			Loss			Equity			Common Stock				Additional Paid In		Accumulated			Accumulated Comprehensive			Total Stockholders’
Balance as of April 1, 2021	-	-	-	-		28,986	$	3	$	109,205	$	(45,320	)	$	-		$	63,888
																				Shares		Amount		Capital		Deficit			Income (Loss)			Equity
Balance as of July 1, 2021																					5,797	$	1	$	109,569	$	(49,506	)	$	(1	)	$	60,063
Stock-based compensation						-		-		362		-			-			362			-		-		297		-			-			297
Foreign currency translation adjustment						-		-		-		-			(1	)		(1	)		-		-		-		-			17			17
Net loss	-	-	-	-		-		-		-		(4,186	)		-			(4,186	)		-		-		-		(4,461	)		-			(4,461	)
Balance as of June 30, 2021	-	-	-	-		28,986	$	3	$	109,567	$	(49,506	)	$	(1	)	$	60,063
Balance as of September 30, 2021																					5,797	$	1	$	109,866	$	(53,967	)	$	16		$	55,916

See Notes to Unaudited Condensed Consolidated Financial Statements.

Vyant Bio, Inc.

Consolidated Statements of Temporary Equity and Common Stockholders’ Equity (Deficit)

(unaudited)

(Shares and USD in Thousands)

Six months ended June 30, 2022 and 2021
																						Shares		Amount		Capital			Deficit			Loss			Equity
Nine months ended September 30, 2022 and 2021																					Nine months ended September 30, 2022 and 2021
					Common Stock				Additional Paid In			Accumulated			Accumulated Comprehensive			Total Stockholders’				Common Stock				Additional Paid In			Accumulated			Accumulated Comprehensive			Total Stockholders’
					Shares		Amount		Capital			Deficit			Loss			Equity				Shares		Amount		Capital			Deficit			Income (Loss)			Equity
Balance as of January 1, 2022	-	-	-	-		28,993	$	3	$	110,174		$	(78,813	)	$	(74	)	$	31,290				5,798	$	1	$	110,176		$	(78,813	)	$	(74	)	$	31,290
Stock-based compensation						-		-		699			-			-			699				-		-		1,079			-			-			1,079
Exercise of stock options						5		-		4			-						4				1		-		4			-						4
Vesting of restricted stock						8		-		-			-			-			-				2		-		-			-			-			-
Issuance of common stock, net of issuance costs						407		-		(250	)		-			-			(250	)			82		-		(250	)		-			-			(250	)
Foreign currency translation adjustment						-		-		-			-			12			12				-		-		-			-			148			148
Net loss	-	-	-	-		-		-		-			(14,968	)		-			(14,968	)			-		-		-			(18,431	)		-			(18,431	)
Balance as of June 30, 2022	-	-	-	-		29,413	$	3	$	110,627		$	(93,781	)	$	(62	)	$	16,787
Balance as of September 30, 2022																							5,883	$	1	$	111,009		$	(97,244	)	$	74		$	13,840

Shares Amount Shares Amount Shares Amount Equity Shares Amount Capital Deficit (Deficit)
Series A
Preferred Stock Series B
Preferred Stock Series C
Preferred Stock Total
Temporary Common Stock Additional Paid In Accumulated
Accumulated
Comprehensive
Total
Common
Stockholders’
Equity
Shares Amount Shares Amount Shares Amount Equity Shares Amount Capital Deficit Loss
(Deficit)
Balance as of January 1, 2021 4,612 $ 12,356 3,489 $ 16,651 - - $ 29,007 2,594 - $ 1,514 $ (37,954 ) $ - $ (36,440 )
Beginning balance 4,612 $ 12,356 3,489 $ 16,651 - - $ 29,007 2,594 - $ 1,514 $ (37,954 ) $ (36,440 )

Stock-based compensation - - - - - - - - - 728 - - 728

Exercise of stock options - - - - - - - - - 4 - - 4
Issuance of Series C Convertible Preferred shares, net of issuance costs of $214 - - - - 567 1,786 1,786 - - - - - -
Issuance of Common Stock for acquisition consideration - - - - - - - 11,007 2 59,918 - - 59,920
Issuance of Incremental shares to StemoniX shareholders upon Merger - - - - - - - 805 - - - - -
Conversion of Preferred Stock to Common Stock upon Merger (4,612 ) (12,356 ) (3,489 ) (16,651 ) (567 ) (1,786 ) (30,793 ) 11,197 1 30,792 - - 30,793
Conversion of 2020 Notes to Common Stock upon Merger - - - - - - - 3,339 - 16,190 - - 16,190
Preferred stock warrant settled for Common Stock upon Merger - - - - - - - 44 - - - - -

Warrant liability reclassified to equity upon Merger - - - - - - - - 421 - - 421
Foreign currency translation adjustment - - - - - - - - - - - (1 ) (1 )
Net loss - - - - - - - - - - (11,552 ) - (11,552 )
Balance as of June 30, 2021 - $ - - $ - - $ - - 28,986 $ 3 $ 109,567 $ (49,506 ) $ (1 ) $ 60,063
Ending balance - $ - - $ - - $ - - 28,986 $ 3 $ 109,567 $ (49,506 ) (1 ) $ 60,063

	Shares			Amount			Shares			Amount			Shares			Amount			Equity			Shares		Amount		Capital		Deficit			Income		(Deficit)
	Series A Preferred Stock						Series B Preferred Stock						Series C Preferred Stock						Total Temporary			Common Stock				Additional Paid In		Accumulated			Accumulated Comprehensive		Total Common Stockholders’ Equity
	Shares			Amount			Shares			Amount			Shares			Amount			Equity			Shares		Amount		Capital		Deficit			Income		(Deficit)
Balance as of January 1, 2021		4,612		$	12,356			3,489		$	16,651			-			-		$	29,007			519		-	$	1,514	$	(37,954	)	$	-	$	(36,440	)
Beginning balance		4,612		$	12,356			3,489		$	16,651			-			-		$	29,007			519		-	$	1,514	$	(37,954	)	$	-	$	(36,440	)

Stock-based compensation		-			-			-			-			-			-			-			-		-		1,025		-			-		1,025

Exercise of stock options		-			-			-			-			-			-			-			-		-		4		-			-		4
Issuance of Series C Convertible Preferred shares, net of issuance costs of $214		-			-			-			-			567			1,786			1,786			-		-		-		-			-		-
Issuance of Common Stock for acquisition consideration		-			-			-			-			-			-			-			2,201		-		59,920		-			-		59,920
Issuance of Incremental shares to StemoniX shareholders upon Merger		-			-			-			-			-			-			-			161		-		-		-			-		-
Conversion of Preferred Stock to Common Stock upon Merger		(4,612	)		(12,356	)		(3,489	)		(16,651	)		(567	)		(1,786	)		(30,793	)		2,239		1		30,792		-			-		30,793
Conversion of 2020 Notes to Common Stock upon Merger		-			-			-			-			-			-			-			668		-		16,190		-			-		16,190
Preferred stock warrant settled for Common Stock upon Merger		-			-			-			-			-			-			-			9		-		-		-			-		-

Warrant liability reclassified to equity upon Merger		-			-			-			-			-			-			-					-		421		-			-		421
Foreign currency translation adjustment		-			-			-			-			-			-			-					-		-					16		16
Net loss		-			-			-			-			-			-			-			-		-		-		(16,013	)		-		(16,013	)
Balance as of September 30, 2021		-		$	-			-		$	-			-		$	-			-			5,797	$	1	$	109,866	$	(53,967	)	$	16	$	55,916
Ending Balance		-		$	-			-		$	-			-		$	-			-			5,797	$	1	$	109,866	$	(53,967	)	$	16	$	55,916

See Notes to Unaudited Condensed Consolidated Financial Statements.

Vyant Bio, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(USD in Thousands)

	2022			2021			2022			2021
	Six months ended June 30,						Nine months ended September 30,
	2022			2021			2022			2021
Cash Flows from Operating Activities:
Net loss	$	(14,968	)	$	(11,552	)	$	(18,431	)	$	(16,013	)
Net loss from discontinuing operations		6,237			240			6,053			1,427
Reconciliation of net loss to net cash used in operating activities, continuing operations:
Stock-based compensation		560			698			865			825
Amortization of operating lease right-of-use assets		171			79			245			211
Depreciation and amortization expense		276			244			400			410
Change in fair value of share-settlement obligation derivative		-			250			-			250
Change in fair value of warrant liability		-			(214	)		-			(214	)
Change in fair value of 2020 Convertible Note with fair value election		-			4			-			4
Accretion of debt discount		-			173			-			173
Loss on conversion of debt		-			2,518			-			2,518
Loss on disposal of equipment		-			6
Gain on sale of assets								-			(14	)
Changes in operating assets and liabilities net of impacts of business combination:
Trade accounts and other receivables		(50	)		34			51			(37	)
Inventory		38			8			409			(66	)
Prepaid expenses and other current assets		(562	)		(1,016	)		(155	)		(469	)
Accounts payable		300			(1,206	)		156			(1,303	)
Obligations under operating leases		(122	)		(103	)		(193	)		(263	)
Accrued expenses and other current liabilities		570			(808	)		563			(756	)
Net cash used in operating activities, continuing operations		(7,550	)		(10,645	)		(10,037	)		(13,317	)
Net cash used in operating activities, discontinuing operations		(585	)		(25	)		(352	)		(673	)
Net cash used in operating activities		(8,135	)		(10,670	)		(10,389	)		(13,990	)
Cash Flows from Investing Activities:
Equipment purchases and leasehold improvements		(361	)		(507	)		(608	)		(521	)
Cash acquired from acquisition		-			30,163			-			30,163
Sale of Patent								-			50
Net cash (used in) provided by investing activities, continuing operations		(361	)		29,656			(608	)		29,692
Net cash used in investing activities, discontinuing operations		(72	)		(13	)		(76	)		-
Net cash (used in) provided by investing activities		(433	)		29,643			(684	)		29,692
Cash Flows from Financing Activities:
Issuance of common stock, net of issuance costs		(246	)		4
Issuance of common stock (net of issuance costs)								(246	)		4
Issuance of Series C Preferred Stock, net of issuance costs		-			1,786			-			1,786
2020 Convertible Note proceeds		-			5,022			-			5,022
Principal payments on long-term debt		-			(82	)		-			(82	)
Proceeds from lease financing								266			-
Principal payments on obligations under finance leases		(72	)		-			(131	)		-
Net cash (used in) provided by financing activities, continuing operations		(318	)		6,730			(111	)		6,730
Net cash used in financing activities, discontinuing operations		(20	)		(10	)		(30	)		(21	)
Net cash (used in) provided by financing activities		(338	)		6,720			(141	)		6,709
Net (decrease) increase in cash and cash equivalents		(8,906	)		25,693			(11,214	)		22,411
Cash and cash equivalents beginning of the period		20,608			792			20,608			792
Cash and cash equivalents end of the period	$	11,702		$	26,485		$	9,394		$	23,203

Supplemental disclosure of cash flow information from continuing operations:
Cash paid for interest	$	14		$	-		$	25		$	-
Cash paid for income taxes		8			-			8			-
Non-cash investing activities from continuing operations:
Fair value of non-cash merger consideration	$	-		$	59,920		$	-		$	59,920
Right-of-use asset obtained in exchange for new lease		1,189			83
Equipment purchases in accounts payable		-			37
Right-of-use asset obtained in exchange for new leases								1,189			83
Non-cash financing activities from continuing operations:
Conversion of Preferred Stock to Common Stock upon Merger	$	-		$	30,793		$	-		$	30,793
Conversion of 2020 Convertible Notes and Accrued Interest to Common Stock upon Merger		-			16,190			-			16,190
Reclass warrant liability to equity upon Merger		-			421			-			421

See Notes to Unaudited Condensed Consolidated Financial Statements.

Vyant Bio, Inc.

Notes to Condensed Consolidated Financial Statements

Period Ended ~~June~~September 30, 2022

(Unaudited)

Note 1. Organization and Description of Business

Vyant Bio, Inc. (the “Company”, “Vyant Bio”, “VYNT” or “we”), is an innovative biotechnology company transforming drug discovery for complex neurodevelopmental and neurodegenerative disorders. Our central nervous system (“CNS”) drug discovery platform combines the scientific knowhow of our team coupled with the application of human-derived organoid models of brain disease, scaled biology, and machine learning. Our platform is designed to: 1) elucidate disease pathophysiology; 2) formulate key therapeutic hypotheses; 3) identify and validate drug targets, cellular assays, and biomarkers to guide candidate molecule selection; and 4) guide clinical trial patient selection and trial design. Our current programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (“~~Rett”~~RTT”), CDKL5 Deficiency Disorders (“CDD”) and familial Parkinson’s Disease (“PD”). The Company’s management believes that drug discovery needs to progressively shift as the widely used preclinical models for predicting safe and effective drugs have under-performed, as evidenced by the time and cost of bringing novel drugs to market. As a result, Vyant Bio is focused on combining sophisticated data science capabilities with highly functional human cell derived disease models. We leverage our ability to identify validated targets and molecular-based biomarkers to screen and test thousands of small molecule compounds in highly standardized human diseased 3D brain organoids in order to create a unique approach to assimilating biological data that supports decision making iteratively throughout the discovery phase of drug development to identify both novel and repurposed drug candidates.

~~As further described~~vivoPharm Sale

On November 2, 2022 the Company completed the sale of its principal vivoPharm subsidiary, vivoPharm LLC, located in ~~Note 3, i~~Hershey, Pennsylvania, to Reaction Biology Corporation for $~~n December 2021,~~5.5 million in an upfront cash payment, subject to customary adjustments for working capital, closing cash, indebtedness and transaction expenses. After these closing adjustments were reflected, $5.5 million was paid at closing. Vyant Bio expects to net approximately $4.4 million in cash after tax and transaction related expenses, as well as incur $0.6 million in exit costs associated with this transaction. Exit costs associated with the vivoPharm business are expected to be paid by March 31, 2023. The Company continues to operate its vivoPharm Australia subsidiary, RDDT a vivoPharm Company Pty Ltd (“RDDT”), which is held for sale.

Reverse Stock Split

On July 14, 2022, the Company’s stockholders approved a reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding shares of Common Stock in the range of one for five to one for fifteen shares. On October 18, 2022, the Company’s Board of Directors approved a ~~plan~~Reverse Split of one for five shares effective November 1, 2022. As a result of the reverse split, every 5 shares of the Company’s Common Stock issued and outstanding were converted into one share of Common Stock. No fractional shares were issued in connection with the reverse split. Stockholders who would otherwise be entitled to ~~sell the~~ ~~vivo~~~~Pharm Pty Ltd and related subsidiaries (“~~~~vivo~~~~Pharm”) business to focus the Company~~a fractional share of Common Stock instead received cash in lieu of fractional shares based on the ~~development~~average of ~~neurological developmental~~the closing sales prices of the Company’s Common Stock as quoted on the Nasdaq Capital Market on the five trading days immediately prior to November 1, 2022. The reverse split did not reduce the number of authorized shares of the Common Stock or preferred stock (the “Preferred Stock”) or change the par values of the Company’s Common Stock or Preferred Stock. The Reverse Split affected all stockholders uniformly and ~~degenerative disease therapeutics. The Company engaged an investment banker~~did not affect any stockholder’s ownership percentage of the Company’s shares of Common Stock (except to the extent that the reverse split would result in ~~December 2021~~some of the stockholders receiving cash in lieu of fractional shares). All outstanding common stock options, warrants and restricted stock units entitling their holders to ~~sell~~receive or purchase shares of the ~~vivo~~~~Pharm business during 2022.~~Company’s Common Stock have been adjusted as a result of the reverse split, as required by the terms of each security. All historical share and per share amounts presented herein have been retroactively adjusted to reflect the impact of the Reverse Split.

The accompanying unaudited condensed consolidated financial statements include all accounts and wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) and reflect all adjustments (including normal recurring accruals) which, in the opinion of management, are considered necessary for the fair presentation of the results for the periods presented. All intercompany transactions have been eliminated. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), the Company has omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited consolidated financial statements of the Company.

No new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements.

These unaudited condensed consolidated financial statements should be read together with the audited consolidated financial statements for the year ended December 31, 2021, and notes thereto included in our Annual Report on Form 10-K as filed with the SEC. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Ultimate results could differ from those estimates. The results of operations for the three and ~~six~~nine months ended ~~June~~September 30, 2022 are not necessarily indicative of the results that may be expected for the entire 2022 year.

Dollar amounts in tables are stated in thousands of U.S. dollars.

Note 2. Cancer Genetics, Inc. Merger

The Company formerly known as Cancer Genetics, Inc. (“CGI”), StemoniX and CGI Acquisition, Inc. (“Merger Sub”) entered into a merger agreement on August 21, 2020, which was amended on February 8, 2021 and February 26, 2021 (as amended, the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, Merger Sub was merged (the “Merger”) with and into StemoniX on March 30, 2021, with StemoniX surviving the Merger as a wholly owned subsidiary of the Company. For U.S. federal income tax purposes, the Merger qualified as a tax-free “reorganization”. Concurrent with the Merger closing, the Company changed its name to Vyant Bio, Inc. Under the terms of the Merger Agreement, upon consummation of the Merger, the Company issued (i) an aggregate of ~~17,977,544~~3,595,508 shares of VYNT common stock, par value $0.0001 per share (the “Common Stock”) to the holders of StemoniX capital stock (after giving effect to the conversion of all StemoniX preferred shares and StemoniX 2020 Convertible Notes) and StemoniX warrants (which does not include a certain warrant (the “Investor Warrant”) issued to a certain StemoniX convertible note holder (the “Major Investor”)), (ii) options to purchase an aggregate of ~~891,780~~178,356 shares of Common Stock to the holders of StemoniX options with exercise prices ranging from $~~0.66~~3.30 to $~~4.61~~23.05 per share and a weighted average exercise price of $~~1.46~~7.30 per share, and (iii) a warrant (the “Major Investor Warrant”) to the Major Investor, expiring February 23, 2026 to purchase ~~143,890~~28,778 shares of Common Stock at a price of $~~5.9059~~29.5295 per share in exchange for the Investor Warrant.

The Merger was accounted for as a reverse acquisition with StemoniX being the accounting acquirer of CGI using the acquisition method of accounting. Under acquisition accounting, the assets and liabilities (including executory contracts, commitments and other obligations) of CGI, as of March 30, 2021, the closing date of the Merger, were recorded at their respective fair values and added to those of StemoniX. Any excess of purchase price consideration over the fair values of the identifiable net assets is recorded as goodwill. The total consideration paid by StemoniX in the Merger amounted to $59.9 million, which represents the fair value of CGI’s ~~11,007,186~~2,201,437 shares of Common Stock or $50.74 million, ~~2,157,686~~431,537 Common Stock warrants or $9.04 million and ~~55,907~~11,181 Common Stock options outstanding on the closing date of the Merger with a fair value of $139 thousand. In addition, at the effective time of the Merger, existing StemoniX shareholders received an additional ~~804,711~~160,942 incremental shares in accordance with the conversion ratio set forth in the Merger Agreement.

The Company incurred $~~165~~ ~~thousand and~~ $2.3 million of costs associated with the Merger that have been reported on the condensed consolidated statement of operations as Merger related costs for the ~~three and six~~nine months ended ~~June~~September 30, ~~2021, respectively. As of June 30, 2021 accounts payable includes $~~20 ~~thousand of Merger-related costs.~~2021.

The following details the allocation of the preliminary purchase price consideration recorded on ~~June~~March 30, 2021, the acquisition date, with adjustments recorded through March 30, 2022, the end of the period for which purchase accounting adjustments can be recorded, and the final purchase price allocation.

Schedule of Preliminary Allocation of the Purchase Price Consideration

	Preliminary		Adjustments			Final
Assets acquired:
Cash and equivalents	$	30,163	$	-		$	30,163
Accounts receivable		705		-			705
Other current assets		806		227			1,033
Intangible assets		9,500		-			9,500
Fixed assets		416		(256	)		160
Goodwill		22,164		216			22,380
Long-term prepaid expenses and other assets		1,381		-			1,381
Total assets acquired	$	65,135	$	187		$	65,322

Liabilities assumed:
Accounts payable and accrued expenses	$	2,670	$	437		$	3,107
Current liabilities of discontinuing operations		588		(141	)		447
Obligations under operating leases		198		-			198
Obligations under finance leases		106		-			106
Deferred revenue		1,293		(114	)		1,179
Payroll and income taxes payable		360		5			365
Total liabilities assumed	$	5,215	$	187		$	5,402

Net assets acquired:	$	59,920	$	-		$	59,920

The Company has completed valuation analyses necessary to assess the fair values of the tangible and intangible assets acquired and liabilities assumed and the amount of goodwill to be recognized as of the acquisition date. Fair values were based on management’s estimates and assumptions. The Company recognized intangible assets related to the Merger, which consist of the tradename valued at $1.5million with an estimated useful life of ten years and customer relationships valued at $8.0million with an estimated useful life of ten years. The initial ~~measurements~~measurement of these intangible assets were classified as Level 3 measurements within the fair value hierarchy. The value of the vivoPharm tradename was determined using the relief from royalty method based on analysis of profitability and review of market royalty rates. The Company determined that a 1.0% royalty rate was appropriate given the business-to-business nature of the vivoPharm operations. The value of the vivoPharm customer relationships was determined using an excess earnings method based on projected discounted cash flows and historic customer data. Key assumptions in this analysis included an estimated 10% annual customer attrition rate based on historical ~~vivo~~~~Pharm~~vivoPharm operations, a blended U.S. federal, state and Australian income tax rate of 27.1%, a present value factor of 8.5% as well as revenue, cost of revenue and operating expense assumptions regarding the future growth, operating expenses, including corporate overhead charges, and required capital investments.

The following presents the unaudited pro forma combined financial information as if the Merger had occurred as of January 1, 2020:

Schedule of Proforma Financial Information

	Three months ended June 30, 2021			Six months ended June 30, 2021			Nine months ended September 30, 2021
Total revenue	$	1,947		$	3,788		$	5,294
Net loss		(4,021	)		(5,560	)		(10,777	)
Pro forma loss per common share, basic and diluted		(0.14	)		(0.19	)		(1.85	)
Pro forma weighted average number of common shares basic and diluted		28,985,924			28,973,370			5,795,520

The pro forma combined results of operations are not necessarily indicative of the results of operations that actually would have occurred had the Merger been completed as of January 1, 2020, nor are they necessarily indicative of future consolidated results.

Note 3. Discontinuing Operations

InIn December 2021, the Company’s Board of Directors approved a plan to sell the business of vivoPharm Pty Ltd and ~~related~~its subsidiaries (“vivoPharm”) ~~business~~ to focus the Company on the development of neurological developmental and degenerative disease therapeutics. In December 2021, the Company engaged an investment bank to sell the vivoPharm business which is expected to be completed 2022.

On November 2, 2022 the Company completed the sale of its principal vivoPharm subsidiary, vivoPharm LLC located in Hershey, Pennsylvania, to Reaction Biology Corporation for $5.5 million in an upfront cash payment, subject to customary adjustments for working capital, closing cash, indebtedness and transaction expenses. After these closing adjustments were reflected, $5.5 million was paid at closing. Vyant Bio expects to net approximately $4.4 million in cash after transaction related expenses and income taxes, as well as incur $0.6 million in exit costs associated with this transaction. Exit costs associated with the vivoPharm business are expected to be paid by March 31, 2023. In connection with the sale of the vivoPharm LLC business, the Company agreed to retain certain liabilities aggregating to $357 thousand.

The Company classified the vivoPharm business as held for sale as of December 31, 2021, and, given the significance of the change in the Company’s strategy, classified this business as discontinuing operations in these condensed consolidated financial statements. Therefore, the results for the three and ~~six~~nine months ended ~~June~~September 30, 2021 have been retroactively restated to reflect the vivoPharm business as discontinuing operations. In connection with the reclassification of the vivoPharm business as held for sale in the fourth quarter of 2021, the Company completed a valuation of the net carrying value of this business and recorded a goodwill impairment charge of $20.2 million. The Company valued the vivoPharm business as of December 31, 2021 equally weighting public company revenue multiples as of December 31, 2021 and comparable transaction revenue multiples, which are classified as Level 3 measurements within the fair value hierarchy. The Company updated the valuation of the vivoPharm business as of March 31, 2022 based on equally weighting public company revenue multiples as of the valuation date and comparable transaction revenue multiples. As a result of this analysis, the Company recorded an additional impairment charge of $4.3 million during the quarter ended March 31, 2022 consisting of the write-off of the remaining $2.2 million goodwill balance and reducing the cost basis of customer relationships and tradenames by $1.8 million and $0.3 million, respectively. During the second quarter of 2022, the Company received two offers for mutually exclusive components of the vivoPharm business and assessed the carrying value of each asset group using the estimated net sales proceeds based on these offers. As a result, the Company recorded a net impairment charge of $1.5million during the second quarter of 2022 which was reduced in the third quarter of 2022 by $388 thousand based upon revised estimated net sales proceeds as of September 30, 2022.

Also included in discontinuing operations are pre-Merger-related payables related to Cancer Genetic’s sale of its BioPharma and Clinical businesses (“Pre-Merger discontinuing operations”). As of ~~June~~September 30, 2022 and December 31, 2021, $~~345~~280 thousand and $409 thousand, respectively, of liabilities relating to these businesses are classified as other current liabilities – discontinuing operations on the Company’s condensed consolidated balance sheets.

Results of discontinuing operations were as follows for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021:

Schedule of Discontinuing Operations from Income Statement and Balance Sheet

	2022			2021			2022			2021
	Three months ended September 30,						Nine months ended September 30,
	2022			2021			2022			2021
Revenue	$	2,140		$	1,251		$	5,180		$	2,887
Cost of goods sold		1,097			952			2,477			1,901
General and administrative		1,287			1,489			3,428			2,419
Impairment charge (recovery) of goodwill and intangible assets		(388	)		-			5,415			-
Total operating costs and expenses		1,996			2,441			11,320			4,320
Income (loss) from discontinuing operations		144			(1,190	)		(6,140	)		(1,433	)
Total other (expense) income		-			3			3			6
Income (loss) from discontinuing operations before income taxes		144			(1,187	)		(6,137	)		(1,427	)
Income tax benefit		40			-			84			-
Net income (loss) from discontinuing operations	$	184		$	(1,187	)	$	(6,053	)	$	(1,427	)

2022 2021 2022 2021
Three months ended
June, 30 Six months ended
June 30,
2022 2021 2022 2021
Revenue $ 1,687 $ 1,618 $ 3,040 $ 1,636
Cost of goods sold 605 924 1,380 949
General and administrative 1,096 928 2,141 930
Impairment of goodwill and intangible assets 1,513 - 5,803 -
Total operating costs and expenses 3,214 1,852 9,324 1,879
Loss from discontinuing operations (1,527 ) (234 ) (6,284 ) (243 )
Total other income 3 2 3 3
Loss from discontinuing operations before income taxes (1,524 ) (232 ) (6,281 ) (240 )
Income tax benefit 44 - 44 -
Net loss from discontinuing operations $ (1,480 ) $ (232 ) $ (6,237 ) $ (240 )

~~Asset~~Assets and liabilities of discontinuing operations were as follows as of ~~June~~September 30, 2022 and December 31, 2021:

	June 30, 2022		December 31, 2021		September 30, 2022		December 31, 2021
Accounts receivable	$	1,631	$	457	$	796	$	457
Other current assets		470		345		326		345
Assets of discontinuing operations - current		2,101		802		1,122		802

Fixed assets, net of accumulated depreciation		237		163		242		163
Operating lease right-of-use assets		891		30		844		30
Intangible assets, net		5,123		8,787		5,511		8,787
Goodwill		-		2,164		-		2,164
Other assets		366		364		366		364
Assets of discontinuing operations - non-current		6,617		11,508		6,963		11,508

Accounts payable	$	1,122	$	358	$	810	$	358
Accrued expense		377		418		363		418
Obligation under operating lease, current		151		29		152		29
Obligation under finance lease, current		31		32		30		32
Deferred revenue		2,260		1,911		1,935		1,911
Taxes payable		321		365		275		365
Other current liabilities		345		409		280		409
Liabilities of discontinued operations - current		4,607		3,522		3,845		3,522

Obligations under operating leases, less current		752		2		709		2
Obligations under finance leases, less current		28		47		19		47
Liabilities of discontinued operations - non-current		780		49		728		49

In January 2022, the vivoPharm business signed an extension to its Hershey, Pennsylvania facility lease and a new lease in South Australia resulting in an increase of $1.0 million of right-of-use (“ROU”) assets and related liability within discontinuing operations.

Intangible assets consisted of the following as of ~~June~~September 30, 2022 and December 31, 2021:

Schedule of Intangible Assets

	June 30, 2022			December 31, 2021			September 30, 2022			December 31, 2021
Customer relationships	$	4,914		$	8,000		$	5,241		$	8,000
Trade name		922			1,500			983			1,500
Intangible assets, net		5,836			9,500			6,224			9,500
Less accumulated amortization		(713	)		(713	)		(713	)		(713	)
Intangible assets, net	$	5,123		$	8,787		$	5,511		$	8,787

Goodwill arising from the Merger was solely attributed to the vivoPharm business. The following is a roll forward of goodwill as of and for the ~~six~~nine months ended ~~June~~September 30, 2022:

Schedule of Goodwill Rollforward

	2022			2022

Beginning balance, January 1	$	2,164		$	2,164
Purchase price adjustments		-			-
Impairment charge		(2,164	)		(2,164	)
Ending balance, June 30	$	-
Ending balance, September 30				$	-

Note 4. Inventory

Inventory consists of the following:

Schedule of Inventory

	June 30, 2022		December 31, 2021		September 30, 2022		December 31, 2021
Finished goods	$	5	$	23	$	-	$	23
Work in process		43		138		59		138
Raw materials		389		314		7		314
Total inventory	$	437	$	475	$	66	$	475

Note 5. Fixed Assets

Presented in the table below are the major classes of fixed assets by category:

Schedule of Fixed Assets

	June 30, 2022			December 31, 2021			September 30, 2022			December 31, 2021
Equipment	$	2,744		$	2,733		$	2,962		$	2,733
Furniture and fixtures		6			6			6			6
Leasehold improvements		580			251			612			251
Fixed assets, gross		3,330			2,990			3,580			2,990
Less accumulated depreciation		(2,229	)		(1,970	)		(2,357	)		(1,970	)
Total	$	1,101		$	1,020		$	1,223		$	1,020

Depreciation expense recognized during the three months ended ~~June~~September 30, 2022 and 2021 was $~~134~~124 thousand and $~~141~~143 thousand, respectively, and for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021, was $~~276~~400 thousand and $~~267~~410 thousand, respectively.

Note 6. Leases

The Company leases its laboratory, research and administrative office space under various operating leases. In January 2022, the Company recorded a $1.2 million ROU asset and related liability upon the signing of a new 5-year lease in San Diego, California.

The components of operating and finance lease expenses for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021 are as follows:

Components of Lease Expense and Supplemental Information

	2022		2021		2022		2021		2022		2021		2022		2021
	Three months ended June, 30				Six months ended June, 30				Three months ended September 30,				Nine months ended September 30,
	2022		2021		2022		2021		2022		2021		2022		2021
Operating lease costs	$	124	$	150	$	222	$	292	$	110	$	149	$	332	$	441
Finance lease costs:
Depreciation of ROU assets		40		-		80		-		61		-		141		-
Interest on lease liabilities		7		-		14		-		11		-		25		-
Total finance lease cost		47		-		94		-		72		-		166		-
Variable lease costs		-		-		-		-		-		-		-		-
Short-term lease costs		-		-		-		-		-		-		-		-
Total lease cost	$	171	$	150	$	316	$	292	$	182	$	149	$	498	$	441

Amounts reported in the condensed consolidated balance sheets as of ~~June~~September 30, 2022 and December 31, 2021 are as follows:

Schedule of Amounts Reported in the Consolidated Balance Sheet

	2022			2021			2022			2021
Operating leases:
Operating lease ROU assets, net	$	1,691		$	673		$	1,617		$	673
Operating lease current liabilities		293			174			303			174
Operating lease long-term liabilities		1,463			516			1,383			516
Total operating lease liabilities		1,756			690			1,686			690
Finance leases:
Equipment		477			477			743			477
Accumulated depreciation		(119	)		(63	)		(181	)		(63	)
Finance leases, net		358			414			562			414
Current installment obligations under finance leases		161			157			247			157
Long-term portion of obligations under finance leases		217			293			338			293
Total finance lease liabilities	$	378		$	450		$	585		$	450

Other information related to leases from continuing operations for the ~~six~~nine months ended ~~June~~September 30, are as follows:

Schedule of Other Information Related to Lease

2022 2021
Supplemental cash flow information:
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow from operating leases $ 122 $ 292
Financing cash flow from finance leases 72 -
Weighted average remaining lease term:
Operating leases 4.94 years 5.68 years
Finance leases 2.25 years -
Weighted average discount rate:
Operating leases 8.3 % 9.9 %
Finance leases 6.5 % -

	2022			2021
Supplemental cash flow information:
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow from operating leases	$	193		$	263
Financing cash flow from finance leases		135			-
Weighted average remaining lease term:
Operating leases		4.69 years			5.68 years
Finance leases		2.29 years			-
Weighted average discount rate:
Operating leases		8.3	%		9.9	%
Finance leases		6.9	%		-

Annual payments of lease liabilities under noncancelable leases from continuing operations as of ~~June~~September 30, 2022 are as follows:

Schedule of Annual Payments of Lease Liabilities Under Noncancelable Leases

Operating leases
Finance leases

Remainder of 2022 $ 212 $ 90
2023 433 181
2024 423 136
2025 427 -
2026 441 -
2027 210 -
Thereafter - -
Total undiscounted lease payments 2,146 407
Less: Imputed interest (390 ) (29 )
Total lease liabilities $ 1,756 $ 378

	Operating leases			Finance leases
Remainder of 2022	$	106		$	70
2023		433			280
2024		423			235
2025		427			51
2026		441			-
2027		215			-
Thereafter		-			-
Total undiscounted lease payments		2,045			636
Less: Imputed interest		(359	)		(51	)
Total lease liabilities	$	1,686		$	585

Note 7. Income Taxes

The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets include, among others, capitalized research and development costs, net operating loss carryforwards and research and development tax credit carryforwards. Deferred tax assets are partially offset by deferred tax liabilities arising from intangibles, fixed assets and lease assets. Realization of net deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain based on the Company’s history of losses. Accordingly, the Company’s net deferred tax assets have been fully offset by a valuation allowance. Utilization of net operating loss and credit carryforwards may be subject to substantial annual limitation due to ownership change provisions of Section 382 of the Internal Revenue Code, as amended and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization.

As of ~~June~~September 30, 2022 and December 31, 2021, the Company’s liability for gross unrecognized tax benefits (excluding interest and penalties) totaled $0 thousand and $0, respectively, in continuing operations. The Company had accrued interest and penalties relating to unrecognized tax benefits of $0 and $0 on a gross basis as of ~~June~~September 30, 2022 and December 31, 2021, respectively, in continuing operations. The Company does not currently expect significant changes in the amount of unrecognized tax benefits during the next twelve months.

Note 8. Long-Term Debt

Long-term debt as of ~~June~~September 30, 2022 and December 31, 2021 consists of a $57 thousand Economic Injury Disaster Loan with annual principal payments of approximately $1 thousand per year.

2020 Convertible Notes

Effective February 8, 2021 the Company’s shareholders and 2020 Convertible Note holders approved amendments to the 2020 Convertible Notes to allow for the issuance of up to $10.0 million in 2020 Convertible Notes for cash (plus up to approximately $3.9 million of 2020 Convertible Notes in exchange for the cancellation of Series B Preferred stock) as well as modifications to the financing’s terms for any 2020 Convertible Noteholder that invested at least $3.0 million of cash since May 4, 2020 in the offering (a “Major Investor”). As of March 12, 2021, the Company completed the $10.0 million 2020 Convertible Note offering. The Company raised approximately $5.0 million from the sale of 2020 Convertible Notes from January 1, 2021 through March 12, 2021 of which approximately $3.9 million were to related parties, including former StemoniX Board members as well as a more than 5% owner of Series B Preferred stock. For any Major Investor, the modified terms provide for a fixed conversion discount on the 2020 Convertible Notes of 20% and a common stock warrant equal to 20% of the amount invested in all 2020 Convertible Notes by such Major Investor divided by the weighted average share price of the Common Stock over the five trading days prior to the closing of the Merger. One 2020 Convertible Note holder that had previously invested $1.25 million in the offering invested an additional $3.0 million on February 23, 2021 and upon the Merger received a warrant to purchase ~~143,890~~28,778 shares of the Company’s common stock at an exercise price of $~~5.9059~~29.5295 per share (the “Major Investor Warrant”). At the time of the Merger, the outstanding principal of the 2020 Convertible Notes of approximately $12.7 million plus accrued interest of $468 thousand were exchanged for ~~3,338,944~~667,788 shares of the Company’s common stock. In connection with this exchange, the Company recorded a debt extinguishment loss of $2.5 million in the first quarter of 2021. The weighted average interest rate on the 2020 notes during the ~~six-month period~~nine-months ended ~~June~~September 30, 2021 was ~~18.22~~18.22%%.

Payroll Protection Plan Loan

In April 2020, the Company applied for and received a $730 thousand loan under the Payroll Protection Plan (“PPP”) as part of the Coronavirus Aid, Relief, and Economic Security Act’s (“CARES Act”). Under the PPP, the Company was able to receive funds for two and a half months of payroll, rent, utilities, and interest cost. In April 2021 the SBA fully forgave the PPP loan. The $730 thousand of PPP loan forgiveness was recorded as a reduction of operating costs during 2020.

Economic Injury Disaster Loan

The Company applied for and received a $57 thousand Economic Injury Disaster Loan (“EIDL”) loan and a $10 thousand grant from the Small Business Administration in connection with the COVID-19 impact on the Company’s business. This loan bears interest at 3.75% and is repayable in monthly installments starting in December 2022 with a final balance due on June 21, 2050.

Note 9. Stockholders’ Equity

Common Stock

Holders of common stock are entitled to one vote per share, to receive dividends if and when declared, and, upon liquidation or dissolution, are entitled to receive all assets available for distribution to stockholders. The holders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. Common stock is subordinate to the preferred stock with respect to dividend rights and rights upon liquidation, winding up and dissolution of the Company.

Lincoln Park Capital Fund, LLC Agreement

On March 28, 2022, the Company entered into a purchase agreement, or Purchase Agreement, with Lincoln Park Capital Fund, LLC (“Lincoln Park”), which, subject to the terms and conditions, provides that the Company has the right to sell to Lincoln Park and Lincoln Park is obligated to purchase up to $15.0 million of its common shares. Additionally, on March 28, 2022, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with Lincoln Park, pursuant to which the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”), covering the resale of shares of common stock issued to Lincoln Park under the Purchase Agreement. In addition, under the Purchase Agreement, the Company agreed to issue a commitment fee of ~~405,953~~81,190 common shares, or the Commitment Shares, as consideration for Lincoln Park entering into the Purchase Agreement. Under the Purchase Agreement, the Company may from time to time for 30 months following May 9, 2022 (the “Commencement Date”), at its discretion, direct Lincoln Park to purchase on any single business day, or a Regular Purchase, up to (i) ~~50,000~~10,000 common shares, (ii) ~~75,000~~15,000 common shares if the closing sale price of its common shares is not below ~~$1.50~~$7.50 per share on Nasdaq or (iii) ~~100,000~~20,000 common shares if the closing sale price of its common shares is not below ~~$2.50~~$12.50 per share on Nasdaq. In addition to Regular Purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases on the terms and subject to the conditions set forth in the Purchase Agreement. In any case, Lincoln Park’s commitment in any single Regular Purchase may not exceed $1.0 million absent a mutual agreement to increase such amount. The purchase price per share for each Regular Purchase will be based on prevailing market prices of the Common Stock immediately preceding the time of sale as computed in accordance with the terms set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park must pay for shares of Common Stock under the Purchase Agreement. The Purchase Agreement may be terminated by the Company at any time after the Commencement Date, at its sole discretion, without any cost or penalty, by giving one business day notice to Lincoln Park to terminate the Purchase Agreement.

At The Market (“ATM”) Financing

On April 8, 2022, the Company entered into an Equity Distribution Agreement (the “Sales Agreement”) with Canaccord Genuity LLC (the “Agent”), pursuant to which the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $20,000,000 (the “Shares”), depending on market demand, with the Agent acting as an agent for sales. Sales of the Shares may be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended (the “Securities Act”), including, without limitation, sales made directly on or through the NASDAQ Capital Market. The Agent will use its commercially reasonable efforts to sell the Shares requested by the Company to be sold on its behalf, consistent with the Agent’s normal trading and sales practices, under the terms and subject to the conditions set forth in the Sales Agreement. The Company has no obligation to sell any of the Shares. The Company may instruct the Agent not to sell the Shares if the sales cannot be effected at or above the price designated by the Company from time to time and the Company may at any time suspend sales pursuant to the Sales Agreement. The Company will pay the Agent a commission of up to 3.0% of the gross proceeds from the sale of Shares by the Agent under the Sales Agreement. The Company has also agreed to reimburse the Agent for its reasonable documented out-of-pocket expenses, including fees and disbursements of its counsel, in the amount of $75,000. In addition, the Company has agreed to provide customary indemnification rights to the Agent. The Offering will terminate upon the earlier of (i) the issuance and sale of all Shares subject to the Sales Agreement, or (ii) the termination of the Sales Agreement as permitted therein, including by either party at any time without liability of any ~~party~~party.

For the three and ~~six~~nine months ended ~~June~~September 30, 2022, the Company incurred $~~149~~0 ~~thousand~~ and $250 thousand, respectively, of issuance costs related to Lincoln Park and Canaccord Genuity LLC ATM arrangements which were recorded in the Condensed Consolidated Statements of Stockholders’ Equity. As of ~~the date of this report,~~September 30, 2022, the Company ~~has~~had not issued any shares of common stock under the Purchase Agreement with Lincoln Park or the Sales Agreement with the Agent, other than the Commitment Shares issued to Lincoln Park.

Preferred Stock

Series A and B Preferred Stock

As of December 31, 2020, the Company had 4,611,587 shares of Series A Preferred Stock (the “Series A Preferred”) 3,489,470 shares of Series B Preferred Stock (the “Series B”) issued and outstanding (collectively the “Preferred Stock”). The Company had classified the Preferred Stock as temporary equity in the condensed consolidated balance sheets as the Preferred Shareholders controlled a Deemed Liquidation Event, as defined below, under the terms of the Series A and Series B Preferred Stock as described below. Effective with the Merger, all the Series A Preferred and the Series B Preferred shares were exchanged for ~~5,973,509~~1,194,701 and ~~4,524,171~~904,834 shares of common stock, respectively, and thethe related carrying value was reclassified to common stock and additional paid-in capital.

Series C Preferred Stock

Effective March 15, 2021, StemoniX’s shareholders approved the Merger with Cancer Genetics and the authorization of $2.0 million of StemoniX’s Series C Preferred Stock (“Series C Preferred”). Effective with the Merger on March 30, 2021, the Series C Preferred shares were exchanged for ~~699,395~~139,879 shares of Vyant Bio common stock and thethe related carrying value was reclassified to common stock and additional paid-in capital.

Warrants

Common Stock Warrants

The Company issued the Investor Warrant on February 23, 2021. Effective with the Merger, the Investor Warrant was exchanged for a warrant to purchase ~~143,890~~28,778 shares of the Company’s common stock at an exercise price of $~~5.9059~~29.5295. Prior to this exchange, the Investor Warrant was classified as a liability and the Company recognized a $214 thousand gain in the first quarter of 2021 related to fair value adjustments. The fair value of the Investor Warrant was $421 thousand at the time of the Merger and reclassified to additional paid in capital.

In connection with the Merger, the Company ~~assume~~assumed d ~~2,157,686~~431,537 common stock warrants issued in prior financings of which ~~2,149,106~~429,820 remain outstanding as of ~~June~~September 30, 2022. A summary of all common stock warrants outstanding as of ~~June~~September 30, 2022 is as follows:

Summary of All Common Stock Warrants Outstanding

Issuance Related to: Exercise Price Outstanding Warrants Expiration Dates
2020 Convertible Note $ 5.91 143,890 Feb 23, 2026
2021 offerings $ 3.50 1,624,140 Feb 10, 2026 - Aug 3, 2026
Advisory fees $ 2.42 - $7.59 492,894 Jan 9, 2024 - Oct 28, 2025
Debt $ 27.60 14,775 Mar 22, 2024
Debt $ 450.00 9,185 Oct 17, 2022 - Dec 7, 2022
Debt $ 300.00 8,112 Oct 17, 2022
Total 2,292,996

Issuance Related to:	Exercise Price		Outstanding Warrants		Expiration Dates
2020 Convertible Note	$	29.55		28,778	Feb 23, 2026
2021 offerings	$	17.50		324,828	Feb 10, 2026 - Aug 3, 2026
Advisory fees	$	12.10 - $37.95		98,578	Jan 9, 2024 - Oct 28, 2025
Debt	$	138.00		2,955	Mar 22, 2024
Debt	$	2,250.00		1,837	Oct 17, 2022 - Dec 7, 2022
Debt	$	1,500.00		1,622	Oct 17, 2022
Total				458,598

Preferred Stock Warrants

In connection with the issuance of the Series A Convertible Preferred and Series B Convertible Preferred, the Company issued warrants (the “Series A Warrants” and “Series B Warrants”, respectively, and collectively, the “Preferred Warrants”) as compensation to non-employee placement agents. The Series A Warrants and Series B Warrants were issued on April 28, 2017 and May 18, 2019, respectively. The Company determined the Preferred Warrants should be classified as equity as they were issued as vested share-based payment compensation to nonemployees. The Preferred Warrants were recorded in stockholders’ equity at fair value upon issuance with no subsequent remeasurement. As part of the Merger, the Preferred Warrants were converted and settled for a total of ~~43,107~~8,621 shares of the Company’s common stock.

Note 10. Fair Value Measurements

During the first quarter of 2021, the Company elected to account for the $3.0 million investment in the 2020 Convertible Notes issued to the Major Investor using the fair value method. Further, the Major Investor Warrant was deemed to be a liability classified instrument due its variable settlement features. Both of these instruments were classified as Level 3 measurements within the fair value hierarchy.

The fair value of the Company’s 2020 Convertible Note issued to the Major Investor is measured as the sum of the instrument’s parts, being the underlying debt instrument and the conversion feature. The conversion feature was valued using the probability weighted conversion price discount. The instrument provided the holder the right to convert the instrument into shares of Series B Preferred Stock at a 20% discount. Given the timing of the issuance of the instrument near the Merger date, management determined that there was a 99.5% probability of the holders converting the instrument to Company shares at a 20% discount.

The Company valued the warrants issued with the 2020 Convertible Notes using a Black-Scholes-Merton model using the value of the underlying stock and exercise price of $2.01, along with a risk-free interest rate of 0.59% and volatility of 86%. The Company estimated the term of the warrant to be 5 years.

The Company’s 2020 Convertible Notes contain a share settled redemption feature (“Embedded Derivative”) that requires conversion at the lesser of specified discounts from qualified financing price per share or the fair value of the common stock at the time of conversion. The discount changes based on the passage of time between issuance of the convertible note and the conversion event. This feature is considered a derivative that requires bifurcation because it provides a specified premium to the holder of the note upon conversion. The Company measures the share-settlement obligation derivative at fair value based on significant inputs that are not observable in the market. This results in the liability classified as a Level 3 measurement within the fair value hierarchy.

Upon the Merger, all of the Level 3 instruments were exchanged for Vyant Bio equity classified instruments. Prior to their exchange, all of these instruments were marked to their fair market values with corresponding changes recorded in the statement of operations in the first quarter of 2021.

In the fourth quarter of 2021, the Company classified the vivoPharm business as discontinuing operations and applied held for sale accounting. The Company valued the vivoPharm business as of December 31, 2021 equally weighting public company revenue multiples as of December 31, 2021 and comparable transaction revenue multiples, which are classified as Level 3 measurements within the fair value hierarchy. The Company updated the valuation of the vivoPharm business during the quarter ending March 31, 2022 based on equally weighting public company revenue multiples and comparable transaction revenue multiples, which resulted in a $4.5million decrease to the fair value of vivoPharm in the first quarter ~~of 2022. The fair value of the~~ ~~vivo~~~~Pharm business was estimated to be $11.0~~ ~~million and $6.5~~ ~~million as of December 31, 2021 and March 31, 2022, respectively.~~of. The Company recognized an impairment charge of $4.3million during the quarter ended March 31, 2022, which decreased vivoPharm’s net carrying value, net of estimated disposal costs from $9.2million as of December 31, 2021 to $4.9million. During the second quarter of 2022, the Company received two offers for mutually exclusive components of the vivoPharm business and assessed the carrying value of each asset group using the estimated net sales proceeds based on these ~~non-binding~~ offers. As a result, the Company recorded a net impairment charge of $1.5million during the second quarter of ~~2022 resulting in a net carrying value~~2022. The Company recorded an impairment recovery of $~~3.7~~388 ~~million for~~thousand during the third quarter of 2022 based upon September 30, 2022 vivoPharm ~~business.~~net assets.

The following tables present changes in fair value of level 3 valued instruments as of and for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021:

Schedule of Changes in Fair Value of Level 3 Valued Instruments

	vivoPharm Business			vivoPharm Business
Balance – December 31, 2021	$	11,000		$	11,000
Additions		-			-
Measurement adjustments		(5,150	)		(5,528	)
Settlement		-			-
Balance – June 30, 2022	$	5,850
Balance – September 30, 2022				$	5,472

	2020 Convertible Note			Warrant			Embedded Derivative			2020 Convertible Note			Warrant			Embedded Derivative
Balance – December 31, 2020	$	-		$	-		$	1,690		$	-		$	-		$	1,690
Additions		3,746			635			325			3,746			635			325
Measurement adjustments		4			(214	)		250			4			(214	)		250
Settlement		(3,750	)		(421	)		(2,265	)		(3,750	)		(421	)		(2,265	)
Balance – June 30, 2021	$	-		$	-		$	-
Balance – September 30, 2021										$	-		$	-		$	-

Note 11. Loss Per Share

Basic loss per share is computed by dividing the net loss after tax attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is computed by including potentially dilutive securities outstanding during the period in the calculation of weighted average shares outstanding. The Company did not have any dilutive securities during the periods presented; therefore, diluted loss per share is equal to basic loss per share.

Presented in the table below is a reconciliation of the numerator and denominator for the basic and diluted ~~loss~~income (loss) per share calculations for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021:

Schedule of Reconciliation of Numerator and Denominator for Basic and Diluted ~~Loss~~Income (Loss) Per Share

2022 2021 2022 2021

Three months ended
June 30,

Six months ended
June 30,

2022 2021 2022 2021
Net loss from continuing operations $ (4,325 ) $ (3,954 ) $ (8,731 ) $ (11,312 )
Net loss from discontinuing operations (1,480 ) (232 ) (6,237 ) (240 )
Net loss $ (5,805 ) $ (4,186 ) $ (14,968 ) $ (11,552 )
Basic and diluted weighted average shares outstanding 29,412,648 28,985,924 29,213,697 16,156,291
Basic and diluted net loss per share:
Continuing operations $ (0.15 ) $ (0.13 ) $ (0.30 ) $ (0.70 )
Discontinuing operations
(0.05
) (0.01 ) (0.21 ) (0.02 )
Net loss per shares attributable to common stockholder, basic and diluted $ (0.20 ) $ (0.14 ) $ (0.51 ) $ (0.72 )

	2022			2021			2022			2021
	Three months ended September 30,						Nine months ended September 30,
	2022			2021			2022			2021
Net loss from continuing operations	$	(3,647	)	$	(3,274	)	$	(12,378	)	$	(14,586	)
Net income (loss) from discontinuing operations		184			(1,187	)		(6,053	)		(1,427	)
Net loss	$	(3,463	)	$	(4,461	)	$	(18,431	)	$	(16,013	)
Basic and diluted weighted average shares outstanding		5,882,560			5,797,162			5,856,159			4,095,951
Basic and diluted net income (loss) per share:
Continuing operations	$	(0.62	)	$	(0.57	)	$	(2.11	)	$	(3.56	)
Discontinuing operations		0.03			(0.20	)		(1.04	)		(0.35	)
Net loss per shares attributable to common stockholder, basic and diluted	$	(0.59	)	$	(0.77	)	$	(3.15	)	$	(3.91	)

The following securities were not included in the computation of diluted shares outstanding for the for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021 because the effect would be anti-dilutive:

Schedule of Computation of Diluted Shares Outstanding

	2022		2021		2022		2021		2022		2021		2022		2021
	Three months ended June 30,				Six months ended June 30,				Three months ended September 30,				Nine months ended September 30,
	2022		2021		2022		2021		2022		2021		2022		2021
Common stock warrants		2,292,996		2,301,576		2,292,996		2,301,576		458,598		460,315		458,598		460,315
Common stock options		2,568,572		2,176,036		2,568,572		2,176,036		484,781		430,567		484,781		430,567
Restricted stock										68,899		-		68,899		-
Total		4,861,568		4,477,612		4,861,568		4,477,612		1,012,278		890,882		1,012,278		890,882
Anti-dilutive securities		4,861,568		4,477,612		4,861,568		4,477,612		1,012,278		890,882		1,012,278		890,882

Note 12. Stock-Based Compensation

The Company has two pre-Merger legacy equity incentive plans: the Cancer Genetics Inc. 2011 Equity Incentive Plan (the “2011 Plan”), and the StemoniX Inc. 2015 Stock Option Plan (the “2015 Plan”, and collectively, the “Frozen Stock Option Plans”). The Frozen Stock Option Plans as well as the 2021 Plan (as defined below) are meant to provide additional incentive to officers, employees and consultants to remain in the Company’s employment. Options granted are generally exercisable for up to 10 years. Effective with the Merger, the Company is no longer able to issue options from the Frozen Stock Option Plans. Effective with the Merger, the Vyant Bio 2021 Equity Incentive Plan (the “2021 Plan”) came into effect, pursuant to which the Company’s Board of Directors may grant up to ~~4,500,000~~900,000 of equity-based instruments to officers, key employees, and non-employee consultants.

As StemoniX was the acquirer for accounting purposes, the pre-Merger vested stock options granted by CGI under the 2008 and 2011 Plans are deemed to have been exchanged for equity awards of the Company. The exchange of StemoniX stock options for options to purchase Company common stock was accounted for as a modification of the StemoniX stock options; however, the modification did not result in any incremental compensation expense as the modification did not increase the fair value of the stock options.

For StemoniX stock options issued prior to the Merger, the expected volatility was estimated based on the average historical volatility of similar entities with publicly traded shares as StemoniX’s shares historically were not publicly traded and its shares rarely traded privately. After the Merger, the Company used Vyant’s historical volatility to determine the expected volatility of post-Merger option grants. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve at the date of grant.

The Company uses a simplified method to determine the expected term for the valuation of employee options. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to options with service conditions. For options granted to nonemployees, the contractual term is used for the valuation of the options.

On March 30, 2021, the Company granted ~~1,151,500~~230,300 stock options to officers and other employees, ~~78,090~~15,618 stock options to independent Board members and a restricted stock unit (“RSU”) of ~~8,676~~1,735 shares to the Company’s Board chair. The options granted to officers and employees vest 2525%% one year from the grant date and thereafter equally over the next 36 months. The options granted to Board members vested upon grant. The Board chair RSU vested one year from the grant date.

During the ~~six~~nine months ended ~~June~~September 30, 2022, the Company granted ~~739,801~~27,516 stock options to officers and other employees and ~~377,714~~81,929 restricted stock units (“RSUs”) to the Company’s Board of Directors. The options granted to officers and employees vest over various terms based on the underlying agreement, as ~~606,720~~121,344 contain performance vesting criteria. The RSUs granted to Board members vest one year from the grant date. As of September 30, 2022 68,899 of the RSU’s remain outstanding.

As of ~~June~~September 30, 2022, there were ~~2,350,674~~492,288 additional shares available for the Company to grant under the 2021 Plan. The grant-date fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option-pricing model. The assumptions for stock option grants during the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021 are provided in the following table.

Schedule of Assumptions for Stock Option Grants

2022 2021
Valuation assumptions
Expected dividend yield 0.0 % 0.0 %
Expected volatility 56.3% –69.8 % 119-123 %
Expected term (years) – simplified method 3.0 – 6.1 5.5 – 6.1
Risk-free interest rate 1.74% – 3.0 % 0.98% – 1.12 %

	2022			2021
Valuation assumptions
Expected dividend yield		0.0	%		0.0	%
Expected volatility		56.3% –70.7	%		70.0%-123.0	%
Expected term (years) – simplified method		3.0 – 6.1			5.5 – 6.1
Risk-free interest rate		2.04% – 3.0	%		0.95% – 1.16	%

Stock option activity during the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021 is as follows:

Schedule of Stock Option Activity

	Number of Options			Weighted average exercise price		Weighted average remaining contractual term		Number of Options			Weighted average exercise price		Weighted average remaining contractual term
Balance as of January 1, 2021		756,383		$	1.82		8.7		151,277		$	9.10		8.7
Granted		1,229,590			4.61				256,187			22.70
Additional options grant StemoniX holders		205,856			4.61				38,376			23.05
Options assumed in Merger		55,840			45.95				11,168			229.75
Exercised		(29,916	)		1.24				(5,983	)		6.20
Forfeited		(34,717	)		2.00				(18,217	)		19.10
Expired		(7,000	)		1.39				(2,241	)		7.25
Balance as of June 30, 2021		2,176,036		$	4.80		9.0
Balance as of September 30, 2021									430,567		$	23.80		8.8

Balance as of January 1, 2022		2,320,097			4.19		7.4		464,019			20.95		7.4
Granted		739,801			1.01				148,860			5.02
Exercised		(5,174	)		0.96				(1,034	)		4.80
Forfeited		(440,385	)		3.54				(94,364	)		14.94
Expired		(45,767	)		25.62				(32,700	)		42.51
Balance as of June 30, 2022		2,568,572		$	2.80		8.2
Balance as of September 30, 2022									484,781		$	15.34		8.2

Exercisable as of June 30, 2022		1,123,471		$	3.50		6.8
Exercisable as of September 30, 2022									198,844		$	19.58		7.1

The weighted average grant-date fair value of options granted during the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021 was $~~0.52~~2.51 and $~~3.89~~19.45, respectively.

The aggregate intrinsic value of options outstanding as of ~~June~~September 30, 2022 was $31 thousand. The intrinsic value of options exercisable as of ~~June~~September 30, 2022 was $21 thousand. The total intrinsic value of options exercised was $15 thousand and $230 thousand for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021, respectively.

The Company recognized stock-based compensation related to different instruments for the three and ~~six~~nine months ended ~~June~~September 30 as follows:

Schedule of Share Based Compensation Activity

	2022		2021		2022		2021			1		2		3		4
	For the three months ended June 30,				For the six months ended June 30,				For the three months ended September 30,				For the nine months ended September 30,
	2022		2021		2022		2021		2022		2021		2022		2021
Stock Options	$	139	$	322	$	397	$	688	$	162	$	117	$	559	$	805
Shares issued for services		143		10		163		10		143		10		306		20
Total	$	282	$	332	$	560	$	698	$	305	$	127	$	865	$	825
Share based compensation	$	282	$	332	$	560	$	698	$	305	$	127	$	865	$	825

As of ~~June~~September 30, 2022, there was $~~2.8~~2.5 million of total unrecognized compensation cost related to unvested stock options granted under the Plan. That cost is expected to be recognized over a weighted average period of ~~2.71~~2.5 years.

Note 13. Segment Information

The Company reports segment information based on how the Company’s chief operating decision maker (“CODM”) regularly reviews operating results, allocates resources and makes decisions regarding business operations. For segment reporting purposes, the Company’s business structure is comprised of one operating and reportable segment.

During the three and ~~six~~nine months ended ~~June~~September 30, 2022, three and ~~six~~four customers accounted for approximately 9591%% and 7876%%, respectively, of the consolidated ~~revenue.~~revenue from continuing operations. During the three and ~~six~~nine months ended ~~June~~September 30, 2021 ~~six and five~~four customers accounted for approximately 8967%% and 7056%% of the respective consolidated ~~revenue.~~revenue from continuing operations.

During the three and ~~six~~nine months ended ~~June~~September 30, 2022, approximately, 4747%% and 4444%,% respectively, of the Company’s consolidated revenue from continuing operations were earned outside of the U.S. During the three and ~~six~~nine months ended ~~June~~September 30, 2021, approximately, 1517%% and 2423%% respectively, of the Company’s consolidated revenue from continuing operations were earned outside of the U.S.

Customers representing 10% or more of the Company’s total revenue from continuing operations for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021 are presented in the table below:

Schedule of Customers Representing Revenues

	Three months ended June 30						Six months ended June 30						Three months ended September 30,						Nine months ended September 30,
	2022			2021			2022			2021			2022			2021			2022			2021
Customer A		49	%		14	%		36	%		19	%		47	%		13	%		39	%		18	%
Customer B		24	%		n/a			13	%		n/a			n/a			12	%		11	%		11	%
Customer C		22	%		10	%		8	%		n/a			n/a			19	%		4	%		12	%
Customer D		n/a			15	%		1	%		8	%		26	%		1	%		16	%		n/a
Customer E		n/a			25	%		n/a			17	%		18	%		n/a			10	%		n/a
Customer F		n/a			4	%		15	%		15	%		n/a			23	%		n/a			15	%
Customer G		n/a			21	%		5	%		11	%

Note 14. Related Party Transactions

The Company raised approximately $3.9 million from the sale of 2020 Convertible Notes from January 1, 2021 through March 12, 2021 from related parties, including former StemoniX Board members as well as one shareholder who owned more than 5% of Series B Preferred stock. This Series B preferred stock shareholder was also a Major Investor and received an Investor Warrant on February 23, 2021. Effective with the Merger, the Investor Warrant was exchanged for a warrant to purchase ~~143,890~~28,778 shares of the Company’s common stock at an exercise price of $~~5.9059~~29.5295 per share.

During the first quarter of 2022, the Company paid a third-party collaboration partner $39 thousand as a reimbursement of third-party costs incurred by the collaborator in connection with the collaboration arrangement. In September 2021, an executive’s family member became an employee of this collaborator. The arrangements with this third-party collaborator had arms-length terms.

Note 15. Contingencies

We are not currently subject to any material legal proceedings. However, we may from time to time become a party to various legal proceedings arising in the ordinary course of our business.

Note 16. Subsequent ~~Event~~Events

vivoPharm Sale

As described in Note 1, on November 2, 2022, the Company closed on a definitive agreement with Reaction Biology Corporation for Reaction to acquire Vyant Bio’s subsidiary vivoPharm LLC, located in Hershey, Pennsylvania.

Reverse Stock Split

As described in Note 1, on July 14, 2022, the Company’s stockholders approved a reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding shares of Common Stock in the range of one for five to one for fifteen shares. On October 18, 2022, the Company’s Board of Directors approved a Reverse Split of one for five shares effective November 1, 2022. As a result of the reverse split, every 5 shares of the Company’s Common Stock issued and outstanding were converted into one share of Common Stock. No fractional shares were issued in connection with the reverse split. Stockholders who would otherwise be entitled to a fractional share of Common Stock instead will receive cash in lieu of fractional shares based on the closing sales price of the Company’s Common Stock as quoted on the Nasdaq Global Market on the five trading days immediately prior to November 1, 2022. The reverse split did not reduce the number of authorized shares of the Common Stock or preferred stock (the “Preferred Stock”) or change the par values of the Company’s Common Stock or Preferred Stock. The Reverse Split affected all stockholders uniformly and did not affect any stockholder’s ownership percentage of the Company’s shares of Common Stock (except to the extent that the reverse split would result in some of the stockholders receiving cash in lieu of fractional shares). All outstanding common stock options, warrants and restricted stock units entitling their holders to receive or purchase shares of the Company’s Common Stock have been adjusted as a result of the reverse split, as required by the terms of each security. All historical share and per share amounts presented herein have been retroactively adjusted to reflect the impact of the Reverse Split.

Equipment Financing Arrangement

In July 2022, the Company signed an equipment financing arrangement to finance $238 thousand of equipment that is expected to be delivered in January 2023. The Company funded a ~~new lease for equipment in its Maple Grove facility. The new~~ $~~three-year~~17 ~~lease commencing in August 2022 requires~~thousand down payment and will make 60 monthly payments of $85 ~~thousand.~~thousand starting in approximately February 2023.

Australian Adult Clinical Trial

The Company’s Australian subsidiary, vivoPharm Pty Ltd, entered into a master services agreement and related statement of work with an Australian contract research organization in November 2022 to support the Company’s adult Rett Syndrome clinical trial. The statement of work aggregates approximately 3.9 million Australian dollars and can be cancelled with 60 days notice.

2122

Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis provides information management believes is useful in understanding the operating results, cash flows and financial condition of Vyant Bio, Inc. The discussion should be read in conjunction with both the unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and related notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations, each included in our Annual Report on Form 10-K for the year ended December 31, 2021. This discussion contains various “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statement entitled “Forward-Looking Statements” located at the end of this Item 2.

Overview

Vyant Bio, Inc. (the “Company”, “Vyant Bio”, “VYNT” or “we”), is an innovative biotechnology company transforming drug discovery for complex neurodevelopmental and neurodegenerative disorders. Our central nervous system (“CNS”) drug discovery platform combines the scientific knowhow of our team coupled with the application of human-derived organoid models of brain disease, scaled biology, and machine ~~learning.~~learning to identify and validate drug targets and therapeutic candidates. Our platform is designed to: 1) elucidate disease pathophysiology; 2) formulate key therapeutic hypotheses; 3) identify and validate drug targets, cellular assays, and biomarkers to guide candidate molecule selection; and 4) guide clinical trial patient selection and trial design. Our current programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (“~~Rett”~~RTT”), CDKL5 Deficiency Disorders (“CDD”) and familial Parkinson’s Disease (“PD”). The Company’s management believes that drug discovery needs to progressively shift as the widely used preclinical models for predicting safe and effective drugs have under-performed, as evidenced by the time and cost of bringing novel drugs to market. As a result, Vyant Bio is focused on combining sophisticated data science capabilities with highly functional human cell derived disease models. We leverage our ability to identify validated targets and molecular-based biomarkers to screen and test thousands of small molecule compounds in human diseased 3D brain organoids in order to create a unique approach to assimilating biological data that supports decision making iteratively throughout the discovery phase of drug development to identify both novel and repurposed drug candidates.

In December 2021, the Company’s Board of Directors approved a plan to sell the business of vivoPharm Pty Ltd (“vivoPharm”) ~~business~~and its subsidiaries to allow the Company to focus on the development of neurological developmental and degenerative disease therapeutics. We engaged an investment banker in December 2021 to sell the vivoPharm business during 2022.

Recent Developments

In July 2022, as part of the Company’s periodic evaluation of factors that impact the Company’s execution of its business, financial and research and development plans, particularly in light of the current status of the overall biotech financial markets, the Company ~~determined to~~will emphasize its operational focus and capital resources on developing therapeutic candidates to treat Rett Syndrome (“~~Rett”~~RTT”). Our specific intent is to be highly focused on the validation of the power of our drug discovery platform in a planned human proof-of-concept clinical trial currently anticipated to begin in early 2023. We have identified an FDA-approved drug and ~~several small molecules~~novel scaffolds against two ~~novel~~distinct targets ~~showing~~that are the ~~molecules robustly and reproducibly rescue the Rett Syndrome disease phenotype in our Rett patient-derived cortical organoid model. Both the repurposed and~~basis for our new chemical entities (“NCE’s”) discovery efforts ~~present~~that in our preclinical discovery work robustly and reproducibly rescue the RTT disease functional phenotype with a differentiated mechanism of action (“MOA”) compared to two compounds currently in U.S. clinical trials. Upcoming milestones for the proof-of-concept program includes an ~~Rett~~RTT adult-population clinical trial expected to commence in early 2023. In November 2022 the Company’s subsidiary, vivoPharm Pty. Ltd. entered into a contract research agreement to commence this clinical trial in Australia in the first quarter of 2023. We ~~have initiated~~are also seeking to be included in a ~~collaboration~~RTT pediatric population clinical trial expected to commence in 2023 as a collaborator with the International Rett Syndrome Foundation ~~to advance our repurposing candidate into a proof-of-concept~~(“ISRF”) if the ISRF receives sufficient funding for this clinical ~~trial in pediatric Rett patients in the U.S. and we plan to file an IND with the FDA in 2023.~~trial. We anticipate identifying our lead series of NCEs for the treatment of ~~Rett~~RTT by the end of the fourth quarter of 2022.

Consistent with the Company’s strategy, the Company will continue its CDD and PD programs with its teams of experts in both areas, although at a ~~reduced~~ slower pace, and expect that development milestones may be delayed as the Company preserves its capital in favor of the Rett ~~programs.~~program.

On November 2, 2022 the Company completed the sale of its principal vivoPharm subsidiary, vivoPharm LLC located in Hershey, Pennsylvania, to Reaction Biology Corporation for $5.5 million in an upfront cash payment, subject to customary adjustments for working capital, closing cash, indebtedness and transaction expenses. After these closing adjustments were reflected, $5.5 million was paid at closing. Vyant Bio expects to net approximately $4.4 million in cash after tax and transaction related expenses, as well as incur $600 thousand in exit costs associated with this transaction. Exit costs associated with the vivoPharm business are expected to be paid by March 31, 2023. The Company continues to operate its wholly-owned vivoPharm subsidiaries vivoPharm Pty. Ltd.,. as well as RDDT, which is held for sale.

Cancer Genetics, Inc. Merger

On March 30, 2021, Vyant Bio, Inc. (the “Company”, “Vyant Bio”, “VYNT” or “we”), formerly known as Cancer Genetics, Inc. (“CGI”), completed its business combination (the “Merger”) with StemoniX, Inc., a Minnesota corporation (“StemoniX”), in accordance with the Agreement and Plan of Merger and Reorganization, dated as of August 21, 2020 (the “Initial Merger Agreement”) by and among the Company, StemoniX and CGI Acquisition, Inc., a Minnesota corporation and wholly-owned subsidiary of the Company (“Merger Sub”), as amended by Amendment No. 1 thereto made and entered into as of February 8, 2021 (the “First Amendment”) and Amendment No. 2 thereto made and entered into as of February 26, 2021 (the “Second Amendment”) (the Initial Merger Agreement, as amended by the First Amendment and Second Amendment, the “Merger Agreement”), pursuant to which Merger Sub merged with and into StemoniX, with StemoniX surviving the Merger as a wholly-owned subsidiary of the Company.

Business Disposals - Discontinuing Operations

In December 2021, vivoPharm, met the criteria to be reported as discontinuing operations. Therefore, the related assets, liabilities, operating results and cash flows of the vivoPharm business are reported as discontinuing operations as of December 31, 2021, and for period from the Merger date of March 30, 2021 through December 31, 2021. See Note 3. Discontinuing Operations, to the condensed consolidated financial statements included in Part I, Item 1 above for additional information.

Revenue from Continuing Operations

The Company’s primary revenue sources are microOrgan plate product sales and prior to the end of the first quarter of 2022 the performance of preclinical drug testing services using our microOrgan technology, referred to as Discovery as a Service, or DaaS. The Company plans to focus its resources on internal drug discovery development programs and will wind down substantially all customer revenue generation in 2022. The Company is seeking a license/distribution partner for its microOrgan plates. During the third quarter, the Company determined that the terms for this business were rapidly unfavorably changing given the overall economic conditions and discussions evolving discussions with a potential partner. As a result, the Company expects revenue for the remainder of 2022 to continue to diminish and inventory associated with this business will be used for internal research and development activities. During the three and ~~six~~nine months ended ~~June~~September 30, 2022, 47% and ~~44 %, respectively, of revenue from continuing operations was generated from customers located outside of the United States. During the three and six months ended June 30, 2021, 15% and 24%~~44%, respectively, of revenue from continuing operations was generated from customers located outside of the United States. During the three and ~~six~~nine months ended ~~June~~September 30, 2021, 17% and 23%, respectively, of revenue from continuing operations was generated from customers located outside of the United States. During the three and nine months ended September 30, 2022, three and ~~six~~four customers accounted for approximately ~~95%~~91% and ~~78%~~76%, respectively, of the consolidated revenue from continuing operations. During the three and ~~six~~nine months ended ~~June~~September 30, 2021, ~~six and five~~four customers accounted for approximately ~~89%~~67% and ~~70%~~56%, respectively, of the consolidated revenue from continuing operations.

Cost of Goods Sold from Continuing Operations

The Company separately reports cost of goods sold for product sales and service revenue. Product revenue costs include labor and product costs such as labware, plates and reagents required to develop iPSC’s into microOrgans as well as overhead, facility and equipment costs at the Company’s Maple Grove, Minnesota facility. As the facility was designed to accommodate the Company’s long-term growth, it has historically operated at less than 25% of capacity. The Company ~~is converting~~substantially completed the conversion of the Maple Grove facility to a research and development facility in the third quarter of 2022 to focus its resources on internal drug discovery programs. Cost of goods sold for service revenue includes internal labor, materials and allocated overhead costs to perform services for DaaS projects.

Operating Expenses from Continuing Operations

The Company classifies its operating expenses into three categories: research and development, selling, general and administrative as well as merger related costs. Operating expenses principally consist of personnel costs including non-cash stock-based compensation, outside services, laboratory consumables, rent, overhead, disease model development costs, and marketing program costs, legal and accounting fees.

Research and Development Expenses. Research and development expenses reflect the personnel related expenses, overhead and lab consumable costs to develop its microOrgan technology at its ~~La Jolla,~~San Diego, California and Maple Grove, Minnesota facilities. The Company intends to accelerate its drug discovery activities in 2022 and beyond.

Selling, General and Administrative Expenses. Selling, general and administrative expenses consist principally of personnel-related expenses, insurance, professional fees, such as legal, accounting, occupancy costs and other general expenses including travel and entertainment expenses.

Merger Related Costs. Merger related costs are direct professional service and investor banker costs incurred by the Company in connection with the Merger.

Coronavirus (COVID-19) Pandemic. On March 11, 2020, the World Health Organization declared the novel strain of coronavirus (“COVID-19”) a global pandemic and recommended containment and mitigation measures worldwide. Many of the Company’s customers worldwide were impacted by COVID-19 and temporarily closed their facilities which impacted revenue in the first half of 2020. While the impact of the pandemic on our business lessened in 2021, the global outbreak of COVID-19 has continued in 2022 with new variants and has impacted the way we operate our business, including remote working, including its impact on technology security risks and employee retention. The extent to which the COVID-19 pandemic may impact the Company’s future business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as, the duration of the outbreak, travel restrictions and social distancing in the U.S. and other countries, business closures or business disruptions, and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease.

The Company is actively monitoring the impact of the COVID-19 pandemic on its business, results of operations and financial condition. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition in the future is unknown at this time and will depend on future developments that are highly unpredictable.

As the Merger was consummated at the close of business on March 30, 2021, the Company’s condensed consolidated statement of operations for the ~~six~~nine months ended ~~June~~September 30, 2021 includes ~~three~~six months and one day of operations associated with the historical CGI business. Further, as noted in Note 3. Discontinuing Operations, to the condensed consolidated financial statements included herein,, the vivoPharm business has been classified as discontinuing operations commencing in the fourth quarter of 2021. Therefore, the results for the three and ~~six~~nine months ended ~~June~~September 30, 2021 have been retroactively restated to reflect the vivoPharm business as discontinuing operations.

Results of Operations

Three and ~~Six Months Ended June~~Nine months ended September 30, 2022 and 2021

The following table sets forth certain information concerning the Company’s results from continuing operations for the periods shown (in thousands):

	Three months ended June 30,						Dollar			%			Six months ended June 30,						Dollar			%			Three months ended September 30,						Dollar			%			Nine months ended September 30,						Dollar			%
	2022			2021			Change			Change			2022			2021			Change			Change			2022			2021			Change			Change			2022			2021			Change			Change
Revenue:
Service	$	-		$	213		$	(213	)		(100	)%	$	94		$	310		$	(216	)		(70	)%	$	-		$	97		$	(97	)		(100	)%	$	94		$	407		$	(313	)		(77	)%
Product		165			116			49			42	%		374			222			152			68	%		152			159			(7	)		(4	)%		526			381			145			38	%
Total revenue	$	165		$	329		$	(164	)		(50	)%	$	468		$	532		$	(64	)		(12	)%	$	152		$	256		$	(104	)		(41	)%	$	620		$	788		$	(168	)		(21	)%

Operating costs and expenses:
Cost of goods sold – service		-			103			(103	)		(100	)%		38			167			(129	)		(77	)%		-			110			(110	)		(100	)%		38			277			(239	)		(86	)%
Cost of goods sold – product		304			345			(41	)		(12	)%		652			741			(89	)		(12	)%		257			355			(98	)		(28	)%		909			1,096			(187	)		(17	)%
Research and development		1,688			910			778			85	%		3,239			1,730			1,509			87	%		1,993			1,211			782			65	%		5,232			2,941			2,291			78	%
Selling, general and administrative		2,509			2,737			(228	)		(8	)%		5,272			3,951			1,321			33	%		1,583			1,856			(273	)		(15	)%		6,855			5,807			1,048			18	%
Merger related costs		-			165			(165	)		(100	)%		-			2,310			(2,310	)		(100	)%		-			-			-			n/a			-			2,310			(2,310	)		(100	)%
Total operating costs and expenses		4,501			4,260			241			6	%		9,201			8,899			302			3	%		3,833			3,532			301			9	%		13,034			12,431			603			5	%
Loss from operations		(4,336	)		(3,931	)		(405	)		10	%		(8,733	)		(8,367	)		(366	)		4	%		(3,681	)		(3,276	)		(405	)		12	%		(12,414	)		(11,643	)		(771	)		7	%

Other (expense) income:
Change in fair value of warrant liability		-			-			-			n/a			-			214			(214	)		(100	)%		-			-			-			n/a			-			214			(214	)		(100	)%
Change in fair value of share-settlement obligation derivative		-			-			-			n/a			-			(250	)		250			(100	)%		-			-			-			n/a			-			(250	)		250			(100	)%
Loss on debt conversions		-			-			-			n/a			-			(2,518	)		2,518			(100	)%		-			-			-			n/a			-			(2,518	)		2,518			(100	)%
Other income (expense), net		11			(23	)		34			(148	)%		2			(391	)		393			(100	)%		34			2			32			1,600	%		36			(389	)		425			(109	)%
Total other (expense) income		11			(23	)		34			(148	)%		2			(2,945	)		2,947			(100	)%		34			2			32			1,600	%		36			(2,943	)		2,979			(101	)%
Loss from continuing operations before income taxes		(4,325	)		(3,954	)		(371	)		9	%		(8,559	)		(11,312	)		2,581			23	%		(3,647	)		(3,274	)		(373	)		11	%		(12,378	)		(14,586	)		2,208			(15	)%
Income tax expense (benefit)		-			-			-						-			-			-			-			-			-			-			n/a			-			-			-			n/a
Net loss from continuing operations	$	(4,325	)	$	(3,954	)	$	(371	)		9	%	$	(8,559	)	$	(11,312	)	$	2,581			23	%	$	(3,647	)	$	(3,274	)	$	(373	)		11	%	$	(12,378	)	$	(14,586	)	$	2,208			(15	)%

Operating results: Comparison for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021

Revenue from Continuing Operations

Total revenue decreased ~~50%~~41%, or ~~$164~~$104 thousand, to ~~$165~~$152 thousand for the three months ended ~~June~~September 30, 2022, as compared with ~~$329~~$256 thousand for the three months ended ~~June~~September 30, 2021.

Total revenue decreased ~~12%~~21%, or ~~$64~~$168 thousand, to ~~$468~~$620 thousand for the ~~six~~nine months ended ~~June~~September 30, 2022, as compared with ~~$532~~$788 thousand for the ~~six~~nine months ended ~~June~~September 30, 2021. The decrease in the current-year periods were the result of our planned decrease in revenue generating activities at our Maple Grove facility as we ~~transition~~transitioned its operations to an internal research and development facility in 2022. Product revenue increased or maintained in the current-year periods as compared with the prior-year periods, primarily from increased shipping volumes as we wind down our customer sales, as well as increased ~~pricing~~.pricing.

Cost of Goods Sold from Continuing Operations

Cost of goods sold – service aggregated ~~$103~~$110 thousand for the three months ended ~~June~~September 30, 2021, resulting in a cost of goods sold of ~~48%~~113% of service revenue. The 2021 period was negatively impacted by incremental costs incurred to achieve contract deliverables. All service revenue contracts were completed in the first quarter of 2022 resulting in no service revenue or cost of sales in the ~~second~~third quarter of 2022.

Cost of goods sold – service aggregated $38 thousand and ~~$167~~$277 thousand, respectively, for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021, resulting in a cost of goods sold of 40% and ~~54%~~68%, respectively, of service revenue. The 2022 period was favorably impacted by a higher margin project and the 2021 period was negatively impacted by incremental costs incurred to achieve contract deliverables.

Cost of goods sold – product aggregated ~~$304~~$257 thousand and ~~$345~~$355 thousand for the three months ended ~~June~~September 30, 2022 and 2021, respectively, resulting in cost of goods sold gross margin deficits of ~~$139~~$105 thousand and ~~$229~~$196 thousand. Cost of goods sold – product aggregated ~~$652~~$909 thousand and ~~$741 thousand~~$1.1 million for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021, respectively, resulting in ~~respective~~ cost of goods sold gross margin deficits of ~~$278~~$383 thousand and ~~$519~~$715 thousand. The decrease in cost of goods sold margin deficits in the current-year periods as compared with the prior-year periods was the result of increased revenue, a decrease in scrap materials and our focus on transforming our Maple Grove location to a research and development facility in 2022.

Operating Expenses from Continuing Operations

Research and development expenses increased by ~~85%~~65%, or ~~$778~~$782 thousand, to ~~$1.7~~$2.0 million for the three months ended ~~June~~September 30, 2022 from ~~$910 thousand~~$1.2 million for the three months ended ~~June~~September 30, 2021. This increase is primarily due to transforming our Maple Grove location to a research and development facility in 2022 which resulted in additional consumables used in research and development instead of being used for manufacturing inventory. Research and development expenses increased by ~~87%~~78%, or ~~$1.5~~$2.3 million, to ~~$3.2~~$5.2 million for the ~~six~~nine months ended ~~June~~September 30, 2022 from ~~$1.7~~$2.9 million for the ~~six~~nine months ended ~~June~~September 30, 2021. This increase is principally due to a ~~$853 thousand~~$1.1 million increase in payroll-related ~~and consulting~~ expenses, ~~a $417~~$892 thousand increase in research and development activities, ~~at our Maple Grove facility,~~ and ~~$230~~$223 thousand related to moving to a new facility in California in order to reduce our annual lease expense in that location.

Selling, general and administrative expenses decreased by 8%15%, or ~~$228~~$273 thousand, to ~~$2.5~~$1.6 million for the three months ended ~~June~~September 30, 2022, as compared with ~~$2.7~~$1.9 million for the three months ended ~~June~~September 30, 2021. This decrease reflects reductions in head count, business development activities and other miscellaneous expense reductions. Selling, general and administrative expenses increased by ~~33%~~18%, or ~~$1.3~~$1 million, to ~~$5.3~~$6.9 million for the ~~six~~nine months ended ~~June~~September 30, 2022, as compared with ~~$4.0~~$5.8 million for the ~~six~~nine months ended ~~June~~September 30, 2021. The 2021 period reflects the Company as a privately-held company during the first quarter whereas the 2022 period reflects the Company as a publicly-held company. The ~~six~~nine months ended ~~June~~September 30, 2022 includes ~~incremental $717 thousand of payroll-related expenses, including~~ one-time severance benefits for two former employees of $437 ~~thousand.~~thousand and $250 thousand in higher professional expenses. The Company incurred ~~$418~~$467 thousand of additional ~~professional fees~~insurance expense in 2022 as compared towith the same ~~prior year~~prior-year period.

Merger related costs for the ~~six~~nine months ended ~~June~~September 30, 2021 were $2.3 million. These professional service-related costs and investment banker fees were incurred related to the Merger.

Other Expenses, net from Continuing Operations

Total other income, net was not significant for the quarter ended ~~June~~September 30, 2022 and 2021.

Total other income, net was not significant for the ~~six~~nine months ended ~~June~~September 30, 2022. Total other expense for the ~~six~~nine months ended ~~June~~September 30, 2021 was $2.9 million, which consisted of a $250 thousand mark-to-market loss for an embedded compound derivative from the 2020 Convertible Notes, $2.5 million loss on the conversion of these notes to equity upon the closing of the Merger, a $214 thousand mark to market warrant liability gain, and interest expense of $368 thousand primarily related to the 2020 Convertible Notes.

Discontinuing Operations

In connection with the Merger, the Company was deemed to be the accounting acquiror of the vivoPharm business on March 30, 2021. Therefore, the vivoPharm business is reflected in discontinued operations for ~~three~~six months and one day in the period ended ~~June~~September 30, 2021.

In the three months ended ~~June~~September 30, 2022, the vivoPharm business generated ~~$1.7~~$2.1 million in revenue and incurred ~~a $1.5 million non-cash~~ net income of $184 thousand. This net income includes an impairment ~~loss. During~~charge recovery of $388 thousand for intangible assets arising from the ~~second quarter of 2022, the Company received two offers for mutually exclusive components of the~~ ~~vivo~~~~Pharm business and assessed the carrying value of each asset group using the estimated net sales proceeds based on these non-binding offers.~~Merger.

In the ~~six~~nine months ended ~~June~~September 30, 2022, the vivoPharm business generated ~~$3.0~~$5.2 million in revenue and incurred a ~~$6.2~~$6.1 million net loss. This net loss includes a goodwill impairment charge of $2.2 million and an impairment charge of ~~$3.6~~$3.2 million for intangible assets arising from the Merger. The impairment loss of ~~$5.8~~$5.4 million during the ~~six~~nine months ended ~~June~~September 30, 2022 was the result of changes in market valuations for contract research organizations infrom December 31, 2021 to September 30, 2022 which impact the ~~first~~Company’s valuation of the vivoPharm business which is accounted for as a held for sale asset since the fourth quarter of ~~March 31, 2022~~2021. Factors such as funding for biotechnology and pharmaceutical companies, higher interest rates and inflation as well as the ~~consideration of~~Ukraine War have all impacted public company stock valuations in 2022 which may result in additional adjustments to the ~~two non-binding offers received in the second quarter of 2022 for mutually exclusive components~~carrying value of the vivoPharm business. In November 2022 the Company sold the vivoPharm US operations and continue to operate the vivoPharm Australian operations within discontinuing operations. The Company expects to incur approximately $600 thousand of exit costs through March 31, 2023 to reduce the cost structure of the remaining vivoPharm employee base.

Liquidity and Capital Resources

The Company’s operating activities have been primarily funded with proceeds from the sale of convertible notes and preferred stock securities. Prior to the Merger, CGI’s primary sources of liquidity had been cash collections from its customers and funds generated from debt and equity financings. The Company is expected to generate minimal revenue from the StemoniX business during the remainder of 2022 as ~~it winds down its~~we have substantially ceased the Maple Grove facility’s revenue producing operations to support ~~its~~ internal drug discovery ~~programs.~~ programs, including its planned adult human clinical trial in Australia that is expected to commence in the first quarter of 2023. The Company had cash and cash equivalents of ~~$11.7~~$9.4 million as of ~~June~~September 30, 2022. The Company’s management has projected that the Company’s cash on hand, together with the net proceeds of approximately $4.4 million from the ~~planned~~ sale of the vivoPharm U.S. business ~~during~~in November 2022 and proceeds from future sales of common stock pursuant to the Purchase Agreement with Lincoln Park Capital, LLC as well as the at-the-market financing with Canaccord Genuity, will be adequate to fund the Company’s currently planned operations into ~~early 2024.~~the fourth quarter of 2023. Such estimate may prove to be wrong, and we could use our available capital resources sooner than we currently expect, and/or the capital resources that we are assuming will be present could fail to materialize at the amounts we project or at ~~all~~.all.

The Company expects to continue to incur operating losses in the future, unless and until the Company’s drug discovery efforts or other revenue from collaborators are able to demonstrate a level of success that would lead to potential out- licensing or sale of therapeutic assets. In addition, the Company will continue to incur the costs of being public, including legal and audit fees and director’s and officer’s liability insurance. These losses have had, and will continue to have, an adverse effect on the Company’s working capital, total assets and stockholders’ equity. Because of the numerous risks and uncertainties associated with drug discovery and development efforts and costs associated with being a public company, the Company is unable to predict when it will become profitable, and it may never become profitable. Even if the Company does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis. The Company’s inability to achieve and then maintain profitability would negatively affect its business, financial condition, results of operations and cash flows.

Lincoln Park Capital Fund, LLC Agreement

At The Market Financing

During the next twelve months, the Company may take further steps to raise additional capital to meet our long-term liquidity needs including, but not limited to, one or more of the following: the licensing of drug candidates with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common stock or other securities via private placements or public offerings. Although the Company has been successful in raising capital in the past, there can be no assurance that additional financing will be available on acceptable terms, if at all, and its negotiating position in capital raising efforts may worsen as existing resources are used. There is also no assurance that the Company will be able to enter into collaborative relationships that will provide sources of liquidity. Additional equity financings may be dilutive to our stockholders. Debt financing, if available, may involve significant cash payment obligations and covenants that restrict the Company’s ability to operate as a business. Licensing or strategic collaborations may result in royalties or other terms which reduce our economic potential from products under development. If the Company is unable to raise the funds necessary to meet its long-term liquidity needs, the Company may have to delay or discontinue the development of one or more discovery programs, license out programs earlier than expected, raise funds at a significant discount or on other unfavorable terms, if at all, or sell all or a part of the business.

In August 2022, in connection with efforts to sell its vivoPharm subsidiary, the Company determined that certain historical vivoPharm tax returns either had not been filed or were incorrectly filed with the U.S. Internal Revenue Service (“IRS”). As a result of this finding, the Company determined that it is more-likely-than not that the tax exposure is not significant to the consolidated financial statements taken as a whole. This conclusion is based on the specific facts related to this matter and how we believe the IRS will treat these facts. ~~We plan to file corrective~~Corrective tax returns were filed with the IRS ~~as soon as possible.~~in September 2022. In the event the IRS does not accept our position, the Company’s tax liability could aggregate up to ~~$3.6~~$2.8 million plus interest and penalties.

The Company’s forecast of the period of time through which its current financial resources will be adequate to support its operations and its expected operating expenses are forward-looking statements and involve risks and uncertainties. Actual results could vary materially and negatively as a result of a number of factors, including those set forth below under “Cautionary Note Regarding Forward-Looking Statements.”

2829

Cash Flows from Continuing Operations

Net cash flow from operating, investing and financing activities from continuing operations for the periods below were as follows (in thousands):

~~Six Months Ended June~~Nine months ended September 30, 2022 and 2021

	Six months ended June 30,						Nine months ended September 30,
	2022			2021			2022			2021
Net cash used in operating activities	$	(7,464	)	$	(10,644	)	$	(10,037	)	$	(13,317	)
Net cash (used in) provided by investing activities		(361	)		29,656			(608	)		29,692
Net cash (used in) provided by financing activities		(318	)		6,730			(111	)		6,730
Net (decrease) increase in cash and cash equivalents from continuing operations	$	(8,143	)	$	25,742		$	(10,756	)	$	23,105

The Company had cash and cash equivalents of ~~$11.7~~$9.4 million and ~~$26.5~~$23.2 million as of ~~June~~September 30, 2022 and 2021, respectively.

Cash Used in Operating Activities

Net cash used in operating activities from continuing operations was ~~$7.5~~$10.0 million for the ~~six~~nine months ending ~~June~~September 30, 2022, consisting of a net loss of ~~$8.7~~$12.4 million, decreased for net non-cash adjustments of ~~$1.0~~$1.5 million and additional cash provided by operating assets and liabilities items of $831 thousand, largely from a reduction of inventory balances as we transitioned the Maple Grove location to a research and development facility as well as an increase in payroll liabilities. In addition, $352 thousand of cash was used in 2022 discontinuing operations.

Net cash used in operating activities from continuing operations was $13.3 million for the nine months ending September 30, 2021, consisting of a net loss of $14.6 million, decreased for net non-cash adjustments of $4.2 million and additional cash used in operating assets and liabilities items of ~~$174 thousand.~~

Net cash used in operating activities from continuing operations was $10.6 million for the six months ending June 30, 2021, consisting of a net loss of $11.3 million, decreased for net non-cash adjustments of $3.8 million and additional cash provided by operating assets and liabilities items of $3.1$2.9 million. The non-cash adjustments include stock-based compensation of $825 thousand, depreciation and amortization expense of $410 thousand and a net loss ~~from conversion~~related to the pre-merger StemoniX capital structure and related debt conversions of ~~debt in the amount of $2.5~~$2.7 million. ~~In operating~~Operating assets and liabilities used net cash ~~used included~~of $2.9 million including a ~~$722 thousand~~$2.1 million reduction in accounts payable and accrued expenses due to Merger related costs being ~~paid at~~payments in 2021. The net loss for the ~~end~~nine months ended September 30, 2021 includes $2.3 million of ~~the first quarter.~~Merger related costs.

Cash Used in Investing Activities

Net cash used in investing activities from continuing operations was ~~$361~~$608 thousand for the ~~six~~nine months ~~ending June~~ended September 30, 2022, related to investments in ~~equipment.~~equipment and our new leased facility in California. Net cash provided by investing activities from continuing operations was $29.7 million for the ~~six~~nine months ended ~~June~~September 30, 2021, principally from CGI cash balances at the close of the Merger.

Cash Used in Financing Activities

Net cash used in financing activities from continuing operations was ~~$318~~$111 thousand for the nine months ended September 30, 2022, primarily related to issuance costs related to the Lincoln Park Capital Fund LLC ~~agreement.~~agreement partially offset by a new financing lease entered into in the third quarter. Net cash provided by financing activities from continuing operations was $6.7 million for the ~~six~~nine months ended ~~June~~September 30, 2021 due to $5.0 million from the issuance of 2020 Convertible Notes and $1.7 million from the issuance of Series Preferred C shares.

Off-Balance Sheet Arrangements

Since inception, the Company has not engaged in any off-balance sheet activities as defined in Item 303(a)(4) of Regulation S-K.

2930

Critical Accounting Policies and Significant Estimates

Critical accounting policies are those policies that require the application of management’s most challenging subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Critical accounting policies involve judgments and uncertainties that are sufficiently likely to result in materially different results under different assumptions and conditions. For the ~~six~~nine months ended ~~June~~September 30, 2022, there were no significant changes in our critical accounting ~~policies.~~ policies except for:

	(a)	As of September 30, 2022 the Company has written off all of its goodwill from the Merger and as the Company sold its vivoPharm US operations in November 2022, unamortized intangible assets are not expected to be material to the Company’s consolidated balance sheet as of December 31, 2022. Therefore, the Company expects that the valuation of goodwill and intangible assets will not be a critical accounting policy as of December 31, 2022; and
	(b)	Given the Company’s exit from selling products and services, which was substantially completed in the third quarter of 2022, the Company no longer considers revenue recognition as a critical accounting policy as of September 30, 2022.

For a detailed description of our other critical accounting policies and significant estimates, see Management’s Discussion and Analysis of Financial Condition and Results of Operations under Item 7 in our Annual Report on Form 10-K for the year ended December 31, 2021.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report on Form 10-Q contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “can,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,” “continue,” “plan,” “point to,” “project,” “predict,” “could,” “intend,” “target,” “potential” and other similar words and expressions of the future.

There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to:

	●	our strategic plans;

	●	our ability to discover and develop novel therapeutics;

	●	our ability to raise additional capital;

	●	our ability to license any therapeutics we develop to larger companies;

	●	the ability of our licensees to achieve milestones under future licensing agreements that will generate revenue for us;

	●	our ability to secure strategic and clinical co-development partnerships with pharmaceutical and biotechnology companies;

	●	our ability to make capital expenditures and to finance operations;

	●	our cash position;

	●	our ability to effectively manage current and future collaboration partnerships, joint venture or acquisition initiatives undertaken by the Company;

	●	our ability to develop and build infrastructure and teams to manage our research and development, partnering and clinical development activities;

	●	our ability to continue to retain and hire key talent;

	●	our ability to sell the remainder of the vivoPharm business and effectively operate the business during the sales process;

	●	~~our ability to correct historical~~ ~~vivo~~~~Pharm tax filings;~~

	●	our ability to deter cyberattacks on our business;

	●	our ability to obtain compounds used for drug discovery and development could be affected as a result of the tensions between Ukraine and Russia; and

	●	the impact of COVID-19 on the economy, demand for our services and products and our operations, including measures taken by government authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties.

3031

The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipate in our forward-looking statements. Please see “Risk Factors” for additional risks which could adversely impact our business and financial performance.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this report or the date of the document incorporated by reference into this report. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith and we believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs or projections will result or be achieved or accomplished.

ITEM 3: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

~~Not applicable.~~The Company continues to operate its facilities in Australia and expects to initiate a Rett Syndrome clinical trial in the first quarter of 2023. The Company is subject to risk for foreign currency exchange rate fluctuations related to the fluctuation between the Australian dollar and the U. S. dollar and the translation of the Australian dollar and Euro to U. S. dollars. The Company currently does not plan to hedge its foreign currency risks but will continue to evaluate this risk.

Item 4: Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company evaluated, under the supervision and with the participation of the principal executive officer and principal financial officer, the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Securities and Exchange Act of 1934, as amended (“Exchange Act”), as of ~~June~~September 30, 2022, the end of the period covered by this report on Form 10-Q. Based on this evaluation, the Company’s President and Chief Executive Officer (principal executive officer) and its Chief Financial Officer (principal financial officer) have concluded that its disclosure controls and procedures were not effective at the reasonable assurance level at ~~June~~September 30, 2022 because of the material weakness in the Company’s internal control over financial reporting related to the accounting for potential impairment of intangible assets that existed at December 31, 2021 that has not been remediated by the end of the period covered by this Quarterly Report on Form 10-Q.

Disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met.

Changes in Internal Control over Financial Reporting

Other than changes related to the remediation activities discussed below, there were no changes in the Company’s internal control over financial reporting during the ~~six~~three months ended ~~June~~September 30, 2022 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Material Weakness in Internal Control over Financial Reporting

A material weakness in the Company’s internal control over financial reporting was reported in “~~Item~~“Item 9A. Controls and Procedures” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 because the Company did not have appropriate controls related to the accounting for potential impairment of intangibles assets. After the Merger, the Company implemented the following enhancements to internal controls to address this material weakness:

●	Hired a new CFO with significant experience in internal controls, US GAAP and financial forecasting;

●	Established a financial planning and analysis function in June 2021 to analyze, forecast and report on the Company’s operations; and

●	Developed a financial model to forecast vivoPharm revenue based on inputs from management.

We determined that the underlying revenue forecasting model to support the determination of cash flows for our vivoPharm business contained data input errors that required additional analysis and validation during the first quarter of 2022. While these data errors did not impact our assessment of the carrying value of our vivoPharm business as of December 31, 2021, the redesign of this control and ongoing testing of its operational effectiveness will not occur until later in 2022. As a result, the Company concluded that the deficiency in our internal control over financial reporting related to revenue and cash flow forecasting would give rise to the level of a material weakness as of December 31, 2021. The Company expects to remediate this control in 2022 through enhanced data validation and management review.

part II – Other information

ITEM 1: LEGAL PROCEEDINGS

We are not currently subject to any material legal proceedings. However, we may from time to time become a party to various legal proceedings arising in the ordinary course of our business.

ITEM 1A: RISK FACTORS

As a smaller reporting company, we are not required to provide the information required by this item. However, we direct you to the risk factors included in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 30, 2022.

ITEM 2: UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3: DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4: MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5: OTHER INFORMATION

None.

3233

ITEM 6: EXHIBITS

Exhibit No.		Description

~~10.1~~3.1		~~Equity Distribution Agreement, dated April 8, 2022, by and between~~Certificate of Amendment of Certificate of Incorporation, as amended, of Vyant Bio, Inc. ~~and Canaccord Genuity LLC~~, dated November 1, 2022 (incorporated by reference to Exhibit ~~1.1~~3.1 of the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on ~~April 11,~~November 2, 2022).

31.1*		Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities and Exchange Act of 1934, as amended.

31.2*		Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities and Exchange Act of 1934, as amended.

32.1**		Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**		Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS*		XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH*		Inline XBRL Taxonomy Extension Schema Document.

101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104*		Cover Page Interactive Data File—the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

* Filed herewith.

** Furnished, not filed.

# Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company hereby undertakes to furnish supplementally copies of any of the omitted schedules upon request by the SEC.

† Indicates a management contract or compensation plan, contract or arrangement.

3334

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on ~~August 22,~~November 14, 2022.

	VYANT BIO, INC.

Date: ~~August 22,~~November 14, 2022	By:	/s/ John A. Roberts
		John A. Roberts
		President and Chief Executive Officer
		(Principal Executive Officer)

		/s/ Andrew D. C. LaFrence
		Andrew D. C. LaFrence
		Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

3435

	Operating leases			Finance leases
Remainder of 2022	$	212		$	90
2023		433			181
2024		423			136
2025		427			-
2026		441			-
2027		210			-
Thereafter		-			-
Total undiscounted lease payments		2,146			407
Less: Imputed interest		(390	)		(29	)
Total lease liabilities	$	1,756		$	378